Nitric Oxide Releasing Devices

Abstract

Nitric oxide releasing particles, coatings, tapes, monoliths and sprayable formulations for reducing standard foreign body response (FBR) to implanted materials, enhancing wound healing and / or increasing vascularization. The particles, coatings, tapes, monoliths and sprayable formulations are formed from biodegradable polymers and NO releasing donor compounds and / or biodegradable polymers that contain pendant NO releasing functional groups.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This patent application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 191,726, filed May 21, 2021, entitled "Nitric Oxide-Releasing Implanted Devices," and U.S. Provisional Patent Application No. 63 / 191,773, filed May 21, 2021, entitled "Extending NO Release from Medical Devices Using Donor Embedded Biodegradable Particles," the contents of which are incorporated by reference herein.

[0002] The present disclosure relates to the use of polymer coatings, tapes, monoliths, or sprays to prevent, treat, or minimize the effects of foreign body responses, particularly to transdermal and / or subcutaneous implants, such as continuous glucose monitors. Medical devices comprising polymer coatings that release nitric oxide over time, and implanted medical devices comprising adhesive polymer tapes or monoliths that release nitric oxide over time, or sprayed with a polymer solution that releases nitric oxide over time, are also disclosed. In some embodiments, the coating comprises a polymer that releases nitric oxide, and in other embodiments, the coating, tape, monolith, or spray comprises embedded particles that comprise a polymer, such as a biodegradable polymer, that releases nitric oxide, and / or that encapsulates a compound, including a small molecule that releases nitric oxide. [Background technology]

[0003] There are many types of medical devices that are implanted in a human or animal patient, including percutaneous and subcutaneous implants.

[0004] Under ideal conditions, the implant initiates the desired host response and does not provoke any undesirable reactions from adjacent or distant tissues. However, interactions between the implant and the tissue surrounding the implant can lead to complications including infection, inflammation and pain, as well as rejection due to implant-induced clotting and allergic foreign body responses.

[0005] One example of a transdermal implant is a glucose monitor, which is implanted percutaneously but is only accurate for a limited period of time due to the host's immune response to the implanted foreign body, called the foreign body response (FBR).

[0006] The FBR begins upon insertion of almost any material into subcutaneous tissue, initiating the wound creation and wound healing cascade. Immediately, proteins adhere to the biomaterial surface in a process called bioadhesion. Initial protein adsorption is an essential part of the overall FBR, since this subsequent interface promotes the adhesion of inflammatory cells and the development of a provisional matrix that subsequently stimulates blood clotting.

[0007] As part of the FBR, macrophages, monocytes, mast cells and fibroblasts are recruited to the implant site and initiate clearance of the foreign body by releasing chemokines and cytokines. As the body attempts to digest the implant, the concentration and type of mediators released induces further cell recruitment and ultimately phagocytosis.

[0008] Since GOx activity is pH-dependent, this process can lead to a sudden drop in local pH to as low as 3.6, disrupting biosensor performance. Although unlikely to prevent all macrophage migration and subsequent phagocytosis at the wound (glucose sensor), the activation state of macrophages (i.e., M1 or M2) can affect the overall FBR. Indeed, macrophages perform three major functions in the body: host defense, wound healing, and immune regulation.

[0009] As FBR progresses, incomplete phagocytosis by activated macrophages leads to fusion of macrophages into foreign body giant cells (FBGCs) in an attempt to further degrade the implant. For example, FBGC formation on polyurethane coatings covering biosensors has been shown to promote degradation of the underlying biomaterial.

[0010] After 1-2 weeks, inflammatory cells deposit a collagen matrix that insulates the implanted device from the native tissue. This collagen encapsulation lacks the microvasculature of native tissue.

[0011] When glucose sensors become encapsulated, accurate measurement of blood glucose is hindered. The extent of encapsulation depends on all other preceding components, including protein adhesion, cell activation, and cytokine signaling, and the rate of progression of the FBR. Collagen encapsulation persists over the life of the device, but this has a negative impact on sensor performance for sensitivity and response (e.g., lag time).

[0012] After protein adhesion / biofouling, the FBR proceeds with inflammatory cells in response to injury, initiating a more severe immune response against the device. For example, mast cells, which are regulators of inflammation, can also have activity towards implanted biosensors. This has been verified by implanting materials in mast cell-sufficient and mast cell-deficient mice. Mast cell-deficient mice implanted with subcutaneous glucose sensors had significantly better sensor performance than mast cell-sufficient mice. Mast cell-deficient mice exhibited reduced fibrosis and inflammation at the implant site. Thus, one approach to address the FBR has been to use “anti-fouling materials” such as polyurethane-coated glucose biosensors.

[0013] The most distinctive outcome of FBR is collagen encapsulation around the foreign body device. Early investigations of capsules formed around sensors focused on the effect of the capsule on glucose diffusion from native tissue. Glucose sensitivity correlated with collagen encapsulation, with thicker collagen resulting in greater sensitivity loss.

[0014] Increased mass transport could increase the lag time and potentially decrease the magnitude and difference in fluctuating between high and low glucose sensor signals. Increased mass transport could potentially be due to collagen capsule thickness, vascular density, or other unanticipated factors related to FBR.

[0015] There are many FBR effects on glucose sensor performance including vascularization, cellular glucose consumption, capsule thickness, capsule diffusion coefficient and capsule porosity. Mathematical modeling suggests that collagen capsule thickness is a significant source of sensor lag time with little effect on sensor response decay, and that sensor decay can be reduced by decreasing capsule density and increasing vascularization around the implanted biosensor. For this reason, biosensors are only accurate for about two weeks before they need to be replaced. The short period over which a biosensor can be used and the instability of the implanted biosensor have led to poor patient compliance.

[0016] Since FBR-related events directly impact the usefulness of CGM devices, considerable research has focused on improving the biocompatibility of these devices as a strategy to improve sensor performance. These strategies range from chemical changes at the tissue-sensor interface, changes in the physical properties of the device, and the release of biologically active molecules that affect tissue response. Examples include compounds that release vascular endothelial growth factor (VEGF) and nitric oxide (see, e.g., Non-Patent Document 1).

[0017] Nichols disclosed that release of nitric oxide (NO) from biomaterials reduces the foreign body response (FBR), but the optimal NO releasing conductor and dose remained unknown. Nichols evaluated polyurethane-coated wire substrates with various NO release characteristics and implanted them in porcine subcutaneous tissue. Histological analysis revealed that materials with short NO release periods (i.e., 24 hours) were insufficient to reduce collagen capsule thickness at 3 and 6 weeks, whereas implants with longer release periods (i.e., 3-14 days) and larger NO payloads reduced collagen encapsulation at both 3 and 6 weeks. The acute inflammatory response was most significantly attenuated by the systems with the longest duration and highest dose of NO release, supporting the idea that these characteristics are most important in avoiding FBR for subcutaneous biomedical applications (e.g., glucose sensors).

[0018] A limitation of NO-releasing coatings is that the "payload" is limited: once all available NO is released, there is no effective way to generate more NO to suppress the foreign body response. Another limitation is that the half-time of nitric oxide release is often too short to delay the onset of the foreign body response.

[0019] One attempt to increase the half-time of nitric oxide release has been to include S-nitrosothiol modified semiporous silica particles capable of nitric oxide (NO) release in polyurethane coatings. Such particles are disclosed, for example, in J. Chem. Soc. 1999, 143: 1311-1323, 2001. Here, thiol precursors are modified to form S-nitrosothiol NO releasing functional groups and are incorporated into the silica network via co-condensation of mercaptosilane and alkoxysilane precursors. Behaving similarly to low molecular weight S-nitrosothiol-containing NO donor compounds, NO release from polymeric silica media was affected by light, temperature, moisture and metal ions. Mark Schoenfisch first pioneered the use of mesoporous silica nanoparticles (MSNs) and demonstrated that the pores to which donor moieties could be attached provide a protective environment for the NO payload.

[0020] Although the use of such MSNs can improve the release kinetics, i.e. extend the release time, when compared to placing the donor moiety on the surface of silica nanoparticles, a drawback of this approach is that the silica particles must be carefully immobilized within the medical device. As these particles are not biodegradable and therefore persistent in the body, it is not desirable to have them detach from the device and remain in the host after the device is removed. Therefore, when these particles are included in a polymer coating covering the glucose sensor, it is important that the particles do not migrate from the coating.

[0021] As with percutaneous implants, there are many problems associated with the surgical implantation of subcutaneous implants, such as artificial joints, pacemakers, etc. There are many potential risks when these medical devices are implanted, even for days or weeks. These risks include infection, poor wound healing, poor blood supply and scarring around the implanted device, any of which can cause damage to the patient. Nitric oxide inhibits microorganisms such as bacteria, viruses and fungi, increases vasculature, promotes wound healing and reduces scarring. However, many NO-releasing functional groups release nitric oxide for a relatively short period of time and are not suitable for preventing these types of injuries. It would be advantageous to provide a coating for these materials that releases nitric oxide for a sufficiently long period of time, which can help minimize the problems associated with the surgical implantation of subcutaneous implants.

[0022] When a subcutaneous implant site becomes infected during or after surgery, the surrounding tissue is infected by microorganisms. Three main categories of infections can occur after surgery. Superficial intermediate infections are caused by organisms that typically grow near or on the skin. The infection usually occurs at the surgical opening. Deep intermediate infections are the second type and occur immediately after surgery at the site of the implant. Skin-residual and airborne bacteria cause deep intermediate infections. These bacteria enter the body by attaching to the implant surface prior to implantation. Although not common, deep intermediate infections can also occur from dormant bacteria in the tissue at the implant site from a previous infection that is activated by being disturbed from dormancy during surgery. The final type of late infection occurs months to years after implantation of the implant. Late infections are caused by dormant blood-borne bacteria that attached to the implant prior to implantation. Blood-borne bacteria colonize the implant and are eventually released from it. Although infusing implants with antimicrobial agents can reduce the risk of infection during surgery, the use of antimicrobial infused implants continues to carry a risk of patient rejection because only certain types of materials can be infused with antimicrobial agents, patients can develop sensitivities to antimicrobial agents, and not all antimicrobial agents work against all types of bacteria.

[0023] Inflammation commonly occurs after any surgical procedure and is the body's response to tissue damage as a result of trauma, infection, foreign body invasion or local cell death, or as part of an immune response.

[0024] Implant-induced clotting is similar to the clotting process that occurs in the body, preventing blood loss from damaged blood vessels. However, the clotting process is triggered by proteins that attach to the implant surface and lose their shape. When this happens, the proteins change conformation, exposing different activation sites, which can trigger an immune system response and the body tries to attack the implant to get rid of the foreign body.

[0025] The triggering of an immune system response can involve inflammation, which can lead to chronic inflammation, in which case the implant will be rejected and will need to be removed from the patient.

[0026] The immune system may encapsulate the implant in an attempt to remove the foreign body from the tissue site by encapsulating the implant in fibrinogen and platelets. Encapsulation of the implant may lead to further complications as a thick layer of fibrous encapsulation may prevent the implant from performing its desired function.

[0027] The bacteria attack the fibrous encapsulation and become embedded in the fibers. Because the fibrous layer is thick, antibacterial agents cannot reach the bacteria, which can multiply and infect the surrounding tissue. In some cases, it is necessary to remove the implant to remove the microorganisms.

[0028] Furthermore, the body may mount an allergic foreign body response, potentially necessitating removal of the implant.

[0029] One way to mitigate these adverse events is to expose the area around the implant to nitric oxide. Nitric oxide is known to reduce the foreign body response (FBR). Furthermore, nitric oxide is anti-inflammatory and can minimize platelet aggregation, thereby minimizing implant-induced clotting. Furthermore, nitric oxide is effective in treating a wide range of bacterial infections, and therefore may be effective against many of the bacteria that may be introduced to the implant, and may be effective against superficial intermediate, deep intermediate, and late infections, especially if nitric oxide release occurs over a period of at least two weeks after implantation.

[0030] The use of nitric oxide releasing coatings on implants results in many of the same limitations observed with nitric oxide release on transdermal implants. With regard to foreign body response, materials with short NO release periods (i.e., 24 hours) were typically insufficient to reduce collagen capsule thickness at 3 and 6 weeks, whereas implants with relatively longer release periods (i.e., 3-14 days) and larger NO payloads revealed significantly reduced collagen encapsulation at both 3 and 6 weeks. Acute inflammatory responses may be mitigated by systems with the longest duration and highest dose of NO release, supporting the notion that these properties are paramount in avoiding FBR for subcutaneous biomedical applications.

[0031] An attempt to protect the NO payload and thus promote long-term release has been to embed crystalline small molecule donor compounds within polymer films. Mark E. Meyerhoff et al. demonstrated that polyurethane films doped with S-nitroso-N-acetyl-penicillamine can release NO amounts over 20 days, similar to endogenous NO levels (see, e.g., J. Biol. Chem. 1999, 143:1311-1323, 2002). In addition, Hopkins et al. (J. Biol. Chem. 1999, 143:1311-1323, 2002) reported covalently immobilized S-nitroso-N-acetyl-penicillamine within silicone rubber that exhibited sustained NO release for 4 months. Both of these examples support the idea that the environment in which the NO donor compound is present affects its stability. The first by Meyerhoff is a hydrophobic polyurethane, and the second by Hopkins is a hydrophobic silicone. Perhaps the drawback of these concepts is that they cannot be applied to those systems included above, which require more hydrophilic materials / coatings / bulk components.

[0032] Thus, it may be advantageous to provide an implant capable of releasing nitric oxide, especially where the release may occur over a relatively long release period. However, one limitation associated with current medical devices, including subdermal implants, but also certain transdermal implants, is that modifying existing implants to include NO-releasing coatings may require a significant amount of regulatory approval, and thus device manufacturers may be unwilling to modify existing devices to release nitric oxide.

[0033] It would be advantageous to provide subcutaneous and / or transdermal implants that release nitric oxide, ideally without any additional regulatory hurdles associated with adding coatings to the implant. The present disclosure provides such implants.

[0034] It would also be advantageous to provide additional methods for suppressing foreign body responses to transdermal glucose biosensors such that the sensors maintain their accuracy over a relatively longer period of time than conventional transdermal glucose biosensors while avoiding the limitations associated with using non-biodegradable materials. It would also be advantageous to have methods for applying coatings to other transdermal and subcutaneous implants that help minimize the effects of the foreign body response. The present disclosure provides such methods and devices for carrying out these methods. [Prior art documents] [Non-patent literature]

[0035] [Non-Patent Document 1] Nichols, Scott P et al. “The effect of nitric oxide surface flux on the foreign body response to subcutaneous implants.” Biomaterials vol.33,27(2012) [Non-Patent Document 2] Riccio et al.,Chem.Mater.2011,23,7,1727-1735(March 7,2011) [Non-Patent Document 3] Brisbois, Handa, Major, Bartlett, and Meyerhoff, “Long-term nitric oxide release and elevated temperature stability with S-nitroso-N-acetylpenicillamine(SNAP)-doped Elast-eon E2As polymer.Biomaterials”, 34:6957-66 (2013) [Non-Patent Document 4] Hopkins, et al, “Achieving Long-Term Biocompatible Silicone via Covalently Immobilized S-Nitroso-N-acetylpenicillamine(SNAP)That Exhibits 4 Months of Sustained Nitric Oxide Release”, ACS Applied Materials&Interfaces,Vol.10,10.1021 / acsami.8b08647(2018) Summary of the Invention [Means for solving the problem]

[0036] In one embodiment, an implant, such as a transdermal implant, is disclosed that includes a coating that includes a biodegradable polymer. In one aspect of this embodiment, the implant is a transdermal continuous glucose monitor.

[0037] In various aspects of this embodiment, the coating can be formed from a biodegradable, biocompatible polymer that contains pendant nitrosothiol (SNO) groups. After implantation, the nitrosothiol groups on the polymer surface are exposed to biological fluids. The nitrosothiol groups then release nitric oxide. The biodegradable polymer can be hydrophilic or hydrophobic, although it may be preferred that the polymer be hydrophobic to slow degradation and extend the release of nitric oxide.

[0038] In another aspect of this embodiment, the coating includes embedded particles, such as microparticles or nanoparticles, which may or may not contain nitrosothiol groups, but are prepared from small molecule and / or polymeric compounds that contain nitrosothiol groups. The biodegradable polymers may be hydrophilic or hydrophobic, although when introduced into a physiological environment exposed to hydrophilic biological fluids, the polymers are preferably hydrophobic to slow the release of nitric oxide.

[0039] In some aspects of these embodiments, the biodegradable polymer comprises monomeric units that are acids, such as lactic acid or glycolic acid, or that are acid anhydrides, such that when the polymer biodegrades, the local pH is acidic. Nitrosothiols tend to release nitric acid more quickly at relatively acidic pH versus neutral pH (Istvan Hornyak, Krisztina Marosi, Levente Kiss, Pal Grof & Zsombor Lacza (2012) Increased stability of S-nitrosothiol solutions via pH modulations, Free Radical Research, 46:2, 214-225), so the presence of a relatively low pH in the local environment (i.e., around 5.5-6.8) may promote nitric oxide release.

[0040] In another embodiment, a subdermal implant is disclosed that includes a coating that includes a biocompatible polymer. In some embodiments, the polymer is biodegradable, and in other embodiments, the polymer is not biodegradable. In some embodiments, the polymer coating includes embedded particles that, in some aspects of these embodiments, are biodegradable particles.

[0041] In some embodiments, a hydrophobic polymer is used in the coating and hydrophilic or amphiphilic particles are embedded in the polymer coating. In other embodiments, a hydrophobic polymer is used in the coating and hydrophobic particles are embedded in the polymer coating. In yet other embodiments, a hydrophilic or amphiphilic polymer is used in the coating and hydrophobic particles are embedded in the polymer coating. In yet other embodiments, a hydrophilic or amphiphilic polymer is used in the coating and hydrophilic or amphiphilic particles are embedded in the polymer coating.

[0042] The loading of the particles in the polymer coating can vary, typically ranging from about 1 to about 50 weight percent, more typically from about 5 to about 40 weight percent, and preferably from about 10 to about 30 weight percent.

[0043] Representative subdermal implants include artificial joints, pacemakers, stents, insulin infusion sets, shunts such as hydrocephiletic shunts, reconstructive cosmetic implants including breast implants, calf implants and buttock implants. With respect to stents, nitric oxide release from a coating on the stent can minimize restenosis.

[0044] In various aspects of this embodiment, the coating can be formed from a biodegradable biocompatible polymer that contains pendant nitrosothiol (SNO) groups. After implantation, the nitrosothiol groups on the polymer surface are exposed to hydrophilic biological fluids. This allows the nitrosothiol groups to release nitric oxide. As the polymer surface biodegrades, new polymer surfaces are continuously exposed. Depending on the hydrophobicity of the polymer, both the internal and surface nitrosothiol groups can deliver their NO payload once the polymer is exposed to moisture, or the internal nitrosothiol groups can be protected and the polymer can continuously release nitric oxide as it biodegrades. The more hydrophilic the polymer, the faster the release of nitric oxide, as release can occur from the polymer or from particles embedded within the polymer as soon as the polymer is fully hydrated.

[0045] Thus, in some embodiments, especially when a hydrophobic polymer is used, nitric oxide is released until the coating is completely biodegraded. In other embodiments, especially when a hydrophilic polymer is used, complete release of nitric oxide can occur immediately after the hydrophilic polymer. When the polymer is a hydrophobic polymer, whether the pendant nitrosothiol groups are present on the polymer or on particles embedded within the polymer, this can result in extended nitric oxide release compared to hydrophilic polymers.

[0046] In some embodiments, the coating is formed from a biodegradable biocompatible polymer that contains pendant nitrosothiol (SNO) groups. After implantation, the nitrosothiol groups on the polymer surface are exposed to biological fluids. This causes the nitrosothiol groups to release nitric oxide. As the polymer surface biodegrades, new polymer surfaces are continuously exposed, which continuously release nitric oxide. Thus, nitric oxide is released until the coating is completely biodegraded. In other embodiments, particles containing nitrosothiol groups are embedded in the polymer coating and released as the coating biodegrades. Nitric oxide is then released from the particles when the nitrosothiol groups react in the local environment.

[0047] In one embodiment, rather than an actual coating, NO-releasing polymers and / or NO-releasing particles embedded in biodegradable polymers can be used to form biodegradable sutures, staples and / or adhesive tapes. These devices can be used, for example, to close wounds or surgical incisions while releasing nitric oxide over time. This can aid in wound healing, increase vascularization, minimize scarring and reduce cases of infection.

[0048] In another embodiment, a surgical adhesive is disclosed that releases nitric oxide over time. In one aspect of this embodiment, the surgical adhesive comprises a biodegradable polymer that contains pendant SNO or other NO-releasing groups and releases nitric oxide over time. The surgical adhesive includes a biodegradable polymer that contains pendant SNO or other NO-releasing groups and releases nitric oxide over time when the functional group reacts under physiological conditions. To include pendant SNO groups, the biodegradable polymer can be made from monomers that include a thiol group, such as thiolactic acid or cysteine, and optionally one or more of glycolic acid, lactic acid, and caprolactone. The resulting polymer includes pendant thiol groups that can be converted to SNO groups using known chemistry before the surgical adhesive is applied. In the case where the polymer includes pendant amine groups, the amine groups can be converted to diazeniumdiolates or other suitable NO-releasing functional groups using known chemistry.

[0049] In another aspect of this embodiment, the surgical adhesive comprises a biodegradable polymer having particles contained therein that include SNO groups or other nitric oxide precursors (NO releasing functional groups), and optionally, the biodegradable polymer can be a hydrophobic biodegradable polymer.

[0050] A surgical adhesive comprising a biodegradable polymer and embedded particles containing SNO or other NO-releasing groups will release nitric oxide as the biodegradable polymer degrades over time, and the NO-releasing groups in the released particles will react under physiological conditions to release NO.

[0051] In any of these embodiments, the polymer may include, in addition to the biodegradable portion, a polymerizable group such as a polyethylene glycol branch and / or a (meth)acrylate group. As defined herein, the (meth)acrylate group, including acrylic acid, methacrylic acid and their C1-6 alkyl esters, may help adhere the surgical adhesive to the surgical or wound site, and the polyethylene glycol group may minimize scarring around the injury / incision. The surgical adhesive has the additional ability to promote healing by releasing nitric oxide.

[0052] In yet another embodiment, a biodegradable scaffold for tissue engineering is disclosed. In one aspect of this embodiment, the scaffold is formed from a biodegradable polymer that includes pendant SNO groups. In another aspect of this embodiment, the scaffold is formed from a biodegradable polymer that includes embedded particles, the particles including one or more compounds. The biodegradable polymer and / or the embedded particles can be the same polymers and particles as described above for the NO-releasing coating.

[0053] In one aspect of this embodiment, the scaffold comprises stem cells and, optionally, various growth factors capable of inducing differentiation of the stem cells into desired cell types. In one aspect of this embodiment, the stem cells proliferate in approximately the same time frame as the scaffold degrades, thereby forming a three-dimensional tissue matrix of approximately the same shape as the scaffold.

[0054] In various embodiments, the polymers and / or compounds containing nitrosothiol groups can release nitric oxide for extended periods of time, such as, for example, one week, two weeks, three weeks, or one month or more.

[0055] Degradation time can be controlled by judicious selection of the monomers used to prepare the biodegradable polymer, as well as the crystallinity, molecular weight and hydrophobicity. For example, polyglycolic acid tends to biodegrade faster than polylactic acid, and copolymers of lactic acid and glycolic acid can be prepared from these monomers in various ratios to control degradation time.

[0056] In any of these embodiments, the biodegradable polymer can be a branched copolymer, a comb copolymer, or a graft copolymer.

[0057] In some embodiments, the hydrophobic particles are embedded within the hydrophilic coating. In other embodiments, the hydrophilic particles are embedded within the hydrophobic coating. In yet other embodiments, the hydrophilic particles are embedded within the hydrophilic coating or the hydrophobic particles are embedded within the hydrophobic coating.

[0058] The biodegradable polymers can be, for example, branched, comb or graft copolymers, terpolymers, etc. Exemplary monomers used to prepare the polymers include, but are not limited to, sugars, amino acids, hydroxy acids such as glycolic acid, lactic acid and hydroxybutyric acid, lactones such as caprolactone, carbonates, amino acids and sugars.

[0059] Sugars form polysaccharides by taking the hemiacetal of the sugar and forming a glycosidic bond that connects it to an alcohol through loss of water. Amino acids can form peptides and proteins, and when the amino acid contains cysteine, the resulting peptide or protein contains a pendant thiol group that can be converted to a nitrosothiol group. Examples of monomers that can be used to form biodegradable polyhydroxycarboxylic acids (a subset of polyesters) include hydroxybutyric acid, glycolic acid, lactic acid, thiolactic acid, and copolymers and terpolymers thereof.

[0060] Also disclosed is a method of treatment using the device described herein.For example, a method of promoting wound healing by applying a surgical adhesive that releases nitric oxide is disclosed.Also disclosed is a method of monitoring glucose levels using a transdermal glucose monitor with a sensor coated with an NO-releasing coating.Also disclosed is a method of minimizing foreign body response to subcutaneous implants by coating the implant with the coating described herein.

[0061] In yet another embodiment, implants such as subdermal implants, and in some aspects of this embodiment, transdermal implants are disclosed that include an adhesive tape or monolith that releases nitric oxide upon exposure to physiological fluids.

[0062] In further embodiments, implants such as subdermal implants, and in some aspects of the embodiments, transdermal implants are disclosed that are sprayed with a polymer solution that releases nitric oxide upon exposure to physiological fluids.

[0063] In one aspect of these embodiments, the tape, monolith, or sprayable formulation comprises a biodegradable polymer.

[0064] In one aspect of these embodiments, the implant is a sensory implant, a neural implant, a cardiac implant, an orthopedic implant, an electrical implant, a contraceptive implant, or a cosmetic implant. In some embodiments, all or a portion of the implant is porous.

[0065] Representative subdermal implants include artificial joints, pacemakers, stents, insulin infusion sets, ports, shunts such as hydrocephiletic shunts, reconstructive cosmetic implants including breast implants, calf implants and buttock implants. With respect to stents, nitric oxide release from a coating on the stent can minimize restenosis.

[0066] In various aspects of this embodiment, the tape, monolith, or sprayable polymer solution can be formed from a biodegradable biocompatible polymer that contains pendant NO-releasing functional groups, such as nitrosothiol (SNO) groups or diazeniumdiolate groups. After implantation, these NO-releasing functional groups on the polymer surface are exposed to biological fluids. The nitrosothiol groups then release nitric oxide. The biodegradable polymer can be hydrophilic or hydrophobic, although it may be preferable for the polymer to be hydrophobic to slow degradation and extend the release of nitric oxide.

[0067] In other aspects of this embodiment, the polymers used in the tapes, monoliths, or sprayable polymer solutions may or may not contain NO-releasing functional groups such as nitrosothiol or diazeniumdiolate groups, but include embedded particles such as microparticles or nanoparticles prepared from small molecule and / or polymeric compounds that contain these groups. When biodegradable polymers are used, they may be hydrophilic or hydrophobic, but the polymers are preferably hydrophobic to slow the release of nitric oxide when introduced into a physiological environment exposed to hydrophilic biological fluids.

[0068] In some aspects of these embodiments, the biodegradable polymer includes monomeric units that are acids, such as lactic acid or glycolic acid, or that are acid anhydrides, such that when the polymer biodegrades, the local pH is acidic. Nitrosothiols tend to release nitric acid more quickly at acidic pH relative to neutral pH, so the presence of a relatively low pH in the local environment (i.e., around 5.5-6.8) can promote nitric oxide release.

[0069] In some embodiments, the tape, monolith or sprayable polymer solution comprises a hydrophobic polymer and hydrophilic or amphiphilic particles are embedded in the polymer in the case of a tape or monolith, or included in the polymer solution in the case of a sprayable coating applied to a medical device.

[0070] In other embodiments, the tape, monolith, or sprayable polymer solution comprises a hydrophobic polymer and hydrophobic particles are embedded in the polymer in the case of a tape or monolith, or included in the polymer solution in the case of a sprayable coating applied to a medical device.

[0071] In yet other embodiments, the tape, monolith or sprayable polymer solution comprises a hydrophilic or amphiphilic polymer and hydrophobic particles are embedded in the polymer in the case of a tape or monolith, or included in the polymer solution in the case of a sprayable coating applied to a medical device.

[0072] In other embodiments, the tape, monolith or sprayable polymer solution comprises a hydrophilic or amphiphilic polymer and hydrophilic or amphiphilic particles are embedded in the polymer in the case of a tape or monolith, or included in the polymer solution in the case of a sprayable coating applied to a medical device.

[0073] The loading of particles in the polymer tape, monolith, or sprayable polymer solution can vary, typically ranging from about 1 to about 50% by weight, more typically from about 5 to about 40% by weight, and preferably from about 10 to about 30% by weight.

[0074] In various aspects of these embodiments, the polymer present in the tape, monolith, or sprayable formulation comprises a biodegradable biocompatible polymer that contains pendant nitrosothiol (SNO) groups. After implantation, the nitrosothiol groups on the polymer surface are exposed to hydrophilic biological fluids. This allows the nitrosothiol groups to release nitric oxide. As the polymer surface biodegrades, new polymer surfaces are continuously exposed. Depending on the hydrophobicity of the polymer, both the internal and surface nitrosothiol groups can deliver their NO payload once the polymer is exposed to moisture, or the internal nitrosothiol groups can be protected and the polymer can continuously release nitric oxide as it biodegrades. The more hydrophilic the polymer, the faster the release of nitric oxide, as release can occur from the polymer or from particles embedded within the polymer as soon as the polymer is fully hydrated.

[0075] Thus, in some embodiments, nitric oxide is released until the tape, monolith, or sprayed coating is completely biodegraded, especially when a hydrophobic polymer is used. In other embodiments, complete release of nitric oxide can occur immediately after implantation, especially when a hydrophilic polymer is used. When the polymer is a hydrophobic polymer, whether the pendant nitrosothiol groups are present on the polymer or on particles embedded within the polymer, this can result in extended nitric oxide release compared to hydrophilic polymers.

[0076] In some embodiments, the tape, monolith, or polymer spray formulation comprises a biodegradable biocompatible polymer containing pendant nitrosothiol (SNO) groups. After implantation, the nitrosothiol groups on the polymer surface are exposed to biological fluids. This causes the nitrosothiol groups to release nitric oxide. As the polymer surface biodegrades, new polymer surfaces are continuously exposed, which continuously release nitric oxide. Thus, nitric oxide is released until the coating is completely biodegraded. In other embodiments, particles containing nitrosothiol groups are embedded in the tape, monolith, or sprayable polymer solution, and are released as the tape, monolith, or coating sprayed on it biodegrades. Nitric oxide is then released from the particles as the nitrosothiol groups react in the local environment.

[0077] In one embodiment, the tape, monolith, or sprayable formulation is applied to the medical implant prior to implantation, for example within hours of implantation, rather than a preformed coating, which may be applied well before the implant is implanted. This allows the implanted medical device to release nitric oxide over time, aiding in wound healing, increasing vascularization, minimizing scarring, and reducing instances of infection.

[0078] In another embodiment, the sprayable formulation is used in a manner similar to a surgical adhesive, but instead of being applied to a wound site, it is applied to an implant surface (and optionally to pores on the surface of a porous implant) rather than to the wound, although in some embodiments the sprayable formulation can be used as a surgical adhesive depending on whether it contains crosslinkable groups that can crosslink on the wound surface, thereby aiding in wound closure.

[0079] In some embodiments, if the biodegradable polymer in the tape, monolith, or sprayable formulation contains pendant SNO groups, the biodegradable polymer can be made from monomers containing thiol groups, such as, for example, thiolactic acid or cysteine, and optionally one or more of glycolic acid, lactic acid, and caprolactone. The resulting polymer contains pendant thiol groups that can be converted to SNO groups using known chemistry before the tape, monolith, or sprayable formulation is applied to an implant. If the polymer contains pendant amine groups, the amine groups can be converted to diazeniumdiolates or other suitable NO-releasing functional groups using known chemistry.

[0080] In other embodiments, rather than a tape, monolith or biodegradable polymer in a sprayable formulation containing pendant SNO groups, particles embedded in a polymer or mixed with a polymer solution contain SNO groups or other nitric oxide precursors (NO releasing functional groups) and, optionally, a biodegradable polymer, which may be a hydrophobic biodegradable polymer.

[0081] The polymers and / or compounds containing nitrosothiol groups can release nitric oxide for extended periods of time, such as, for example, one week, two weeks, three weeks, or one month or more.

[0082] In any of these embodiments, the polymer may include, in addition to the biodegradable portion, polymerizable groups such as polyethylene glycol branches and / or (meth)acrylate groups. As defined herein, the (meth)acrylate groups, including acrylic acid, methacrylic acid and their C1-6 alkyl esters, may aid in adhering the tape, monolith and / or sprayable formulation to the implant, and the polyethylene glycol groups may minimize scarring around the implant site.

[0083] Degradation time can be controlled by judicious selection of the monomers used to prepare the biodegradable polymer, as well as the crystallinity, molecular weight and hydrophobicity. For example, polyglycolic acid tends to biodegrade faster than polylactic acid, and copolymers of lactic acid and glycolic acid can be prepared from these monomers in various ratios to control degradation time.

[0084] In any of these embodiments, the biodegradable polymer can be a branched, comb or graft copolymer. The biodegradable polymer can be, for example, a branched, comb or graft copolymer, a terpolymer, etc. Exemplary monomers used to prepare the polymers include, but are not limited to, sugars, amino acids, hydroxy acids such as glycolic acid, lactic acid and hydroxybutyric acid, lactones such as caprolactone, carbonates, amino acids and sugars.

[0085] Sugars form polysaccharides by taking the hemiacetal of the sugar and forming a glycosidic bond that connects it to an alcohol through loss of water. Amino acids can form peptides and proteins, and when the amino acid contains cysteine, the resulting peptide or protein contains a pendant thiol group that can be converted to a nitrosothiol group. Examples of monomers that can be used to form biodegradable polyhydroxycarboxylic acids (a subset of polyesters) include hydroxybutyric acid, glycolic acid, lactic acid, thiolactic acid, and copolymers and terpolymers thereof.

[0086] Also disclosed are methods of treatment using the devices described herein, such as minimizing a foreign body response to an implanted medical device by applying the tapes, monoliths, or sprayable formulations described herein onto the implanted medical device and allowing the NO-releasing functional groups in the tapes, monoliths, and / or sprayable formulations to release nitric oxide over time.

[0087] The present invention will be better understood with reference to the following detailed description. [Brief description of the drawings]

[0088] [Figure 1] FIG. 1 is a schematic diagram of a polymer coating containing NO-releasing biodegradable particles adhered to a medical device, the medical device being implanted subcutaneously within a host. [Diagram 2] FIG. 1 is a schematic diagram of a polymer coating containing NO-releasing biodegradable particles adhered to a medical device, the medical device being implanted subcutaneously within a host, showing the particles being released from the coating as the polymer degrades. [Diagram 3] FIG. 1 is a schematic diagram of a wound gel or surgical adhesive comprising NO-releasing biodegradable particles, the adhesive or gel being placed within a wound site. [Figure 4] FIG. 1 is a schematic diagram of a tissue engineering scaffold formed from a polymer containing NO-releasing biodegradable particles, in which NO can be released to promote tissue growth, increase vascularization, and / or reduce scar tissue formation. [Diagram 5] FIG. 1 is a schematic diagram of the foreign body response over time to an implanted glucose sensor. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0089] Detailed Description of the Invention In one embodiment, devices and methods are disclosed for releasing exogenous NO from implantable materials and devices, such as transdermal and subcutaneous implants. The release of exogenous NO can improve local healing and reduce the FBR to the materials and devices after implantation. In certain embodiments of the implantable device, nitric oxide release occurs over a period of weeks to months to reduce the foreign body response to the device over a relatively long period of time.

[0090] In some embodiments, a key factor for the stability of NO to the donor moiety (NO-releasing functional group on the polymer or small molecule) is the water content stored or deployed inside the device. After implantation in a wet environment (i.e., tissue perfused with aqueous biological fluid), it may be advantageous to keep the NO donor dry. If the implant can be kept relatively dry, for example, by using hydrophobic polymers in a coating or particles encapsulated in the coating, or in a tape, monolith, or sprayable formulation, or particles encapsulated in a tape or monolith or present in a sprayable formulation, NO remains bound to the donor for a relatively long period of time than when using hydrophilic polymers. When the NO-releasing compound is exposed to water (or water vapor), the rate at which NO is released increases dramatically. Unfortunately, for some medical devices, such as glucose sensors and wound care adhesives, it is necessary to tolerate a high water content at least around the portion of the operating glucose sensor where the electrodes are present. However, the upper and lower regions of the portion of the operating glucose sensor can be coated with hydrophobic polymers.

[0091] The transcutaneous glucose sensor includes two portions: a first portion is an active sensing area where the electrodes or other sensing portion determine the glucose concentration in the interstitial space of the user's tissue, and a second portion operably connects the first portion of the implantable glucose sensor to a glucose monitor portion that covers the user's skin and allows the first portion of the implantable glucose sensor to penetrate the user's skin to a desired depth.

[0092] In the case of glucose sensors, the outermost polymer coating must be able to diffuse glucose to their sensing area. The highly polar carbohydrate (glucose) structure requires many water molecules to facilitate its diffusion. For this reason, glucose sensors typically contain materials with a water content of 5% by weight or more.

[0093] For surgical dressings and wound care adhesives, water diffusion and solubility within these products is also a requirement for cellular processes and cell proliferation to be promoted to complete host healing. As with glucose sensors, these materials must allow the passage of metabolic products such as glucose while simultaneously facilitating the diffusion of cellular waste products.

[0094] In some embodiments, the important factor for the stability of NO to the donor portion is the water content stored or deployed inside the device.After implantation in a wet environment (i.e., tissue perfused with aqueous biological fluid), it may be advantageous to keep the NO donor dry.If the implant can be kept relatively dry, for example, by using hydrophobic polymers in the tape, monolith, or sprayable formulation, or in particles encapsulated in the tape or monolith, or present in the sprayable formulation, NO remains bound to the donor for a relatively long period of time than when using hydrophilic polymers.When the NO-releasing compound is exposed to water (or water vapor), the rate at which NO is released increases dramatically.

[0095] The components of the medical devices described herein, their preparation and use in the medical devices are described in detail below.

[0096] polymer Polymeric materials are commonly used in connection with implanted medical devices because of their ease of manufacture, flexibility and their biocompatible nature, as well as their wide range of mechanical, electrical, chemical and thermal behavior when combined with different materials as composites. The polymeric material must also have substantial tensile strength and be able to accommodate the device over the expected life of the implant.

[0097] The polymer when adhered, sprayed or coated onto the medical device, or in some embodiments the polymer used to make the medical device itself, contains NO-releasing functional groups or contains embedded particles or small molecules that contain such NO-releasing functional groups. This section describes the polymers, and in a later section, methods are disclosed for functionalizing the polymer or particles or compounds embedded within the polymer such that the polymer contains pendant NO-releasing functional groups.

[0098] Although in some cases it is possible to directly prepare polymers containing NO-releasing functional groups, these functional groups are relatively unstable to a variety of reaction conditions, particularly those that involve exposing the functional groups to light, heat, moisture, or pH levels below about 7. Thus, it is typically easier to first form a polymer with pendant functional groups that can react to form NO-releasing functional groups, and then convert the pendant functional groups to NO-releasing functional groups.

[0099] As used herein, the term "polymer" has the meaning generally given to the term. Examples include homopolymers, copolymers (including block and graft copolymers), dendritic polymers, crosslinked polymers, and the like. Suitable polymers include synthetic and natural polymers (e.g., polysaccharides, peptides), as well as polymers prepared by condensation, addition, and ring-opening polymerization. Also included are rubbers, fibers, and plastics. The polymers can be hydrophilic, amphiphilic, or hydrophobic. In one aspect, the polymers are non-peptide polymers. In some embodiments, the polymers are biocompatible and / or biodegradable. Certain classes of polymers can be either hydrophilic or hydrophobic, depending on the monomers used to prepare the polymer, the degree of polymerization, etc. Certain hydrophilic polymers and certain hydrophobic polymers may be biodegradable, while others may not.

[0100] A hydrophilic polymer or polymer blend is one in which a film or particle of the polymer increases in size by greater than 5% by weight when placed in an aqueous solution of phosphate buffered saline (0.9% salinity, pH 7.4) at 37° C. for 24 hours or more.

[0101] A hydrophobic polymer or polymer blend is one in which a film or particle of the polymer does not increase in size by more than 5% by weight when placed in an aqueous solution of phosphate buffered saline (0.9% salinity, pH 7.4) at 37°C for more than 24 hours.

[0102] Biocompatible and biostable polymers are widely used to package implanted devices with key criteria including the gas and water permeability of the packaged polymer to protect the device's electronic circuitry from moisture and ions inside the human body.

[0103] Non-degradable polymers are often used when the medical device is an implant, such as a pacemaker, hip joint, etc., that is intended to remain in place for an extended period of time. Exemplary non-degradable polymers used in conjunction with implanted medical devices include polyurethane, polyvinylidene fluoride, polyethylene, polypropylene, polydimethylsiloxane, parylene, polyamide, polytetrafluoroethylene, poly(methyl methacrylate), and polyimide, many of which are hydrophobic. In total hip replacements, bearing systems typically use ultra-high-molecular-weight polyethylene (UHMWPE) inserts articulated with cobalt-chromium alloys or ceramics to restore function to damaged or diseased joints.

[0104] Several polymeric implants and prostheses are used in clinical practice. One of the most common applications is the synthetic meniscus. The meniscus is a cartilage tissue that functions to distribute friction in the knee joint. Artificial menisci can be prepared using collagen, polyurethane, polyvinyl alcohol, hyaluronic acid, polycaprolactone, and combinations thereof.

[0105] A polymer with pendant -S-NO groups is referred to as an S-nitrosated polymer. A polymer with pendant -S-NO2 groups is referred to as an S-nitrated polymer. The "-S-NO2 group" is also referred to as sulfonyl nitrate, S-nitrothiol, or thionitrate. The -SNO and -S-NO2 groups decompose in vivo, resulting in the delivery of NO. In one embodiment, the S-nitrated polymer also has a pendant -O-NOX group. The S-nitrated polymer has at least one NO2 group per 1200 atomic mass units of the polymer, preferably at least one NO2 group per 600 amu of the polymer, and even more preferably at least one NO2 group per 70 amu of the polymer, with a similar concentration of NO groups on the S-nitrosated polymer and on the polymer with the diazeniumdiolate group.

[0106] Hydrogels In some aspects of these embodiments, the polymer is water insoluble and hydrophilic and can form a hydrogel. A hydrogel is a composition that can absorb large amounts of water. Polymers capable of forming hydrogels are generally more biocompatible than other polymers and can be used, for example, in devices inserted into the vascular system. Hydrogels also generally exhibit a very mild foreign body reaction during soft tissue implantation.

[0107] The polymers that form the hydrogel are typically crosslinked hydrophilic polymers. Further description and examples of hydrogels are provided in Hydrogels and Biodegradable Polymers for Bioapplications, editors Attenbrite, Huang and Park, ACS Symposium Series, No. 627 (1996), U.S. Patent Nos. 5,476,654, 5,498,613 and 5,487,898, the teachings of which are incorporated herein by reference.

[0108] Examples of hydrogels include polyethylene glycol, polysaccharides and cross-linked polysaccharides, and Eudragit® polymers which contain ethylene glycol and propylene glycol chains.

[0109] Biodegradable Polymers Biodegradable polymers are polymers that meet the requirements of biocompatibility and biodegrade into harmless end products.The polymers described below are intended to be modified to include one or more NO-releasing functional groups.In the following polymer descriptions, the polymers are disclosed as incorporating functional groups that can be converted into NO-releasing compounds, and elsewhere herein, methods are disclosed for converting these functional groups into NO-releasing compounds.

[0110] Biodegradable polymers can be, for example, branched, comb or graft copolymers, terpolymers, etc. Representative monomers used to prepare polymers include, but are not limited to, sugars, amino acids, hydroxy acids such as glycolic and lactic acids, hydroxybutyric acid, and lactones such as caprolactone. Suitable polymers include polyhydroxy acids, polyanhydrides, polyhydroxyalkanoates, polyesteramides, aliphatic copolyesters, and aromatic copolyesters. Examples of monomers that can be used to form biodegradable polyhydroxy acids (polyesters) include hydroxybutyric acid, glycolic acid, lactic acid, thiolactic acid, and copolymers and terpolymers thereof.

[0111] One representative class of biodegradable polymers is the linear polyesters (PLGA) based on lactic acid, glycolic acid, and their mixtures and copolymers. PLGA degrades to lactic acid and glycolic acid by ester hydrolysis and has been shown to have excellent biocompatibility. Polycaprolactone and polycarbonate moieties are also biodegradable and monomers can be incorporated into PLGA polymers.

[0112] Sugars form polysaccharides by taking the hemiacetal of the sugar and forming a glycosidic bond that connects it to an alcohol through loss of water. Amino acids can form peptides and proteins, and when the amino acid contains cysteine, the resulting peptide or protein contains a pendant thiol group that can be converted to a nitrosothiol group. If the amino acid contains lysine, the pendant amine group can be converted to a diazeniumdiolate.

[0113] In embodiments where the biodegradable polymer comprises monomeric units that are acids, such as lactic acid or glycolic acid, or monomeric units that are acid anhydrides, when the polymer biodegrades, the local pH is acidic. The presence of a relatively low pH in the local environment (i.e., around 5.5-6.8) may promote nitric oxide release, since NO-releasing groups, such as diazeniumdiolates and / or nitrosothiols, tend to release nitric oxide more quickly at relatively acidic pH relative to neutral pH.

[0114] Thiol groups can be incorporated into the polymer by incorporating monomers having one or more pendant thiol groups, such as thiolactic acid or cysteine, into the polymerization reaction. The concentration of the thiol-containing monomer can vary depending on the desired amount of NO release, but typically ranges from about 1 to about 50% by weight, more typically from about 5 to about 25% by weight, and most typically from about 10 to about 20% by weight.

[0115] If the thiol group may interfere with the polymerization chemistry or be converted to another functional group and not available for subsequent nitrosation to form a nitrosothiol group, the thiol group can be protected during the polymerization process and subsequently deprotected. Protecting groups for thiols are well known to those of skill in the art.

[0116] PLGA coatings on medical devices degrade by bulk erosion at a uniform rate throughout the matrix. The degradation process is self-catalyzed, since the number of terminal carboxylic acid groups increases with increasing chain scission and acid catalyzes hydrolysis. Degradation is highly dependent on the ratio of lactide to glycoside moieties, as lactide is more hydrophobic and slows down the degradation rate. Also important factors in the degradation process are the crystallinity, molecular weight and glass transition temperature of the polymer. By controlling the ratio of lactic acid to glycolic acid and / or incorporating carbonates and / or caprolactones into the polymer backbone, the resulting polymer can be relatively hydrophobic or relatively hydrophilic.

[0117] Hydrophilic Polymers Hydrophilic polymers have a strong affinity for water. They can be composed of either synthetic polymers, such as polyvinylpyrrolidone and polyethylene glycol, or natural polymers, such as proteins and polysaccharides.

[0118] Amino acids can form peptides and proteins, and when the amino acid contains cysteine, the resulting peptide or protein contains a pendant thiol group that can be converted to a nitrosothiol group.

[0119] Polysaccharides are an example of a hydrophilic polymer. Sugars form polysaccharides by taking the hemiacetal of the sugar and forming a glycosidic bond that bonds it to an alcohol through the loss of water.

[0120] Representative polysaccharides include cyclodextrins such as α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin starch, dextrin, dextran, ficoll, cellulose, fucoidan, alginic acid, carrageenans such as K-carrageenan, glycosaminoglycans such as hyaluronic acid, chondroitin and glucosamine.

[0121] Starch includes relatively low molecular weight highly branched starch (maltodextrin, average molecular weight about 5,000 Da). Starch can be covalently modified with acrylic groups to convert it into a form that can be solidified into microspheres, and polyacryl starch can be converted into granular form by radical polymerization in emulsion (see, for example, Characterization of Polyacryl Starch Microparticles as Carriers for Proteins and Drugs, Artursson et al, J Pharm Sci, 73, 1507-1513, 1984).

[0122] Ficoll is a neutral, highly branched, high mass, hydrophilic polysaccharide that is readily soluble in aqueous solutions. Ficoll is prepared by reacting polysaccharides with epichlorohydrin.

[0123] Dextran is a complex branched glucan (a polysaccharide derived from the condensation of glucose). IUPAC defines dextran as "a branched poly-α-d-glucoside of microbial origin, with glycosidic linkages mainly at C-1 → C-6". The dextran chains vary in length (3-2000 kilodaltons). The polymer backbone consists of α-1,6 glycosidic bonds between glucose monomers, with branching from α-1,3 bonds. This characteristic branching distinguishes dextran from dextrin, which is a linear glucose polymer linked by α-1,4 or α-1,6 bonds.

[0124] Chitosan is a linear polysaccharide composed of randomly distributed β-(1→4) linked D-glucosamine (the deacetylated unit) and N-acetyl-D-glucosamine (the acetylated unit). It is typically produced by treating the chitin shells of crustaceans with alkaline substances such as sodium hydroxide.

[0125] Cellulose is a linear polymer of D-glucose units linked by β(1→4)-glycosidic bonds. Cellulose derivatives, including cellulose esters and cellulose ethers, can also be utilized. Representative cellulose esters include cellulose acetate, cellulose triacetate, cellulose propionate, cellulose acetate propionate (CAP) and cellulose acetate butyrate (CAB). Representative cellulose ethers include carboxymethyl cellulose (CMC), ethyl hydroxyethyl cellulose, hydroxypropyl methyl cellulose (HPMC), hydroxyethyl methyl cellulose, hydroxypropyl cellulose (HPC), hydroxyethyl cellulose, ethyl methyl cellulose, ethyl cellulose and methyl cellulose.

[0126] Other suitable examples are disclosed in Bioactive Carbohydrates, Kennedy and White eds., (John Wiley Sons), Chapter 8, pages 142-182 (1983), the teachings of which are incorporated herein by reference. The polysaccharides have pendant primary and secondary alcohol groups. As a result, S-nitrosylated polysaccharides can be prepared from polythiolated polysaccharides by the methods described herein.

[0127] Polysaccharides can be converted to polythiolated polysaccharides, for example, by the methods disclosed in Gaddell and Defaye and Rojas et al. In these methods, primary alcohols are preferentially thiolated over secondary alcohols. Preferably, a sufficient excess of thiolation reagent is used to form a perthiolated polysaccharide. A polysaccharide is "perthiolated" when all of the primary alcohols have been converted to thiol groups.

[0128] In another aspect, polythiolated polysaccharides can be prepared by reacting alcohol groups, preferably primary alcohol groups, on the polysaccharide with a reagent that adds a moiety containing a free thiol or a protected thiol to the alcohol. In one example, the polysaccharide is reacted with bisisocyanatoalkyl disulfide, followed by reduction to functionalize the alcohol. Conditions for carrying out this reaction can be found in Cellulose and its Derivatives, Fukamota, Yamada and Tonami, eds. (John Wiley & Sons), Chapter 40, (1985), the teachings of which are incorporated herein by reference.

[0129] The polysaccharides can also be modified to include one or more thiol-containing sugars, such as: [ka]

[0130] Glucosamine and galactosamine are naturally occurring amino acid sugars: [ka]

[0131] These and other amine-containing sugars can be used to prepare polysaccharides with pendant diazeniumdiolate groups.

[0132] Hydrophobic Polymers Medical devices coated with hydrophobic biocompatible polymers with pendant NO-releasing groups or embedded particles or small molecules with such groups can achieve sustained local release of nitric oxide. These hydrophobic polymers can also be stable for a certain period of time and then degrade to allow cell / tissue growth. These biocompatible hydrophobic polymers can be used for drug delivery, tissue augmentation and regenerative medicine applications.

[0133] Synthetic hydrophobic polymers can be divided into two groups:

[0134] 1. Prepolymerized: These polymers are prepolymerized from these monomers and include, for example, poly(ε-caprolactone) (PCL), poly(lactic acid) (PLA), poly(D,L-lactic-co-glycolic acid) (PLGA) and polystyrene.

[0135] 2. In process polymerization: These polymers are synthesized from monomers during the preparation of the particles and include, for example, poly(alkyl cyanoacrylate), poly(isobutyl cyanoacrylate), poly(butyl cyanoacrylate), poly(methyl methacrylate), and poly(hexal cyanoacrylate).

[0136] Synthetic polymers have the advantage of sustained release over a period of days to weeks, compared to the relatively short duration of drug release of natural polymers.These other advantages include the use of organic solvents and the requirement of typical conditions during encapsulation.Polymer NPs have therefore been widely studied as drug delivery systems over the past decades, including clinical studies of biodegradable polymer NPs such as PLA and PLGA approved by the US Food and Drug Administration (FDA).

[0137] Representative hydrophobic biodegradable injectable polymers include aliphatic polyesters, polycarbonates and polyanhydrides, including those prepared from lactic acid, glycolic acid, caprolactone, aliphatic diols and diacids, hydroxy fatty acids, and triglycerides such as castor oil.

[0138] Poly(orthoesters) are highly hydrophobic polymers that contain acid-sensitive bonds in the polymer backbone. At a physiological pH of 7.4, these bonds undergo a very slow rate of hydrolysis, but as the ambient pH decreases, the rate of hydrolysis increases, for example, upon exposure to physiological fluids. The hydrophobicity of these polymers limits water penetration, thus halting erosion of the surface and resulting in limited release of nitric oxide.

[0139] The degradation rate of hydrophobic polymers can often be controlled, for example, by adjusting the type and ratio of monomers used to prepare them. For example, PCPP and PCPP-SA 85:15 (poly[bis(p-carboxyphenoxy)propane anhydride] and its copolymer with sebacic acid) have a nearly constant erosion rate over several months. By varying the CPP / SA ratio, almost any degradation rate can be obtained, from one day to three years (Leong, KW, Brott, BC, and Langer, R., J. Biomed. Mater. Res. (25). Copyright (C) 1985 John Wiley & Sons. Inc.).

[0140] For example, Rahmani, Mehran, "List of Hydrophobic Polymers and Coatings, 10.13140 / RG.2.2.26536.72960 (2019) discloses further hydrophobic polymers.

[0141] In some embodiments, the polymers are not brittle and, as a result, remain adhered to the medical device even under physiological conditions. These types of polymers are particularly suitable for coating devices that are implanted in patients for extended periods of time.

[0142] Conversion of polymers to polymers with pendant NO-releasing functional groups After the polymer is formed, the pendant functional groups on the polymer can be converted to NO-releasing functional groups. This same chemistry can be used to convert pendant functional groups on small molecules to NO-releasing functional groups.

[0143] Polymers with pendant NO-releasing functional groups can be prepared from polymers with a number of nucleophilic functional groups, including amines, thiols, hydroxy, hydroxylamine, hydrazine, amide, guanadine, imine, aromatic rings, and nucleophilic carbon atoms (such as protons alpha to carbonyl moieties that are relatively basic when removed by the addition of base to form nucleophilic enolate ions that can react with nitric oxide). However, thiols, such as primary thiols, are particularly preferred, and amines, such as secondary amines, may also be preferred, because they form nitrosothiols and diazeniumdiolates. Each of these functional groups may be preferred for various embodiments, with nitrosothiols being preferred when sustained release of nitric oxide over a long period of time, such as days to weeks, and diazeniumdiolates being preferred when nitric oxide release over a relatively short period of time, such as minutes or hours, is desired.

[0144] To prepare a nitrosylated polymer, a polymer having multiple pendant nucleophilic groups is reacted with a nitrosylating agent under conditions suitable to nitrosylate the nucleophilic groups. To prepare a nitrated polymer, a polymer having multiple pendant nucleophilic groups is reacted with a nitrating agent under conditions suitable to nitrate the nucleophilic groups.

[0145] The preparation of nitrated and nitrosylated polymers is described with respect to S-nitrosylated and S-nitrated polymers. It should be understood that the procedures described herein for preparing S-nitrosylated and S-nitrated polymers can be used for the nitration or nitrosylation of polymers having pendant nucleophilic groups other than the thiols described above. Even if some modifications in conditions are required, such modifications can be determined by one skilled in the art with only routine experimentation.

[0146] S-nitrosylated and S-nitrated polymers can be prepared from polymers having multiple pendant thiol groups, referred to herein as "polythiolated polymers." To prepare an S-nitrosylated polymer, the polythiolated polymer is reacted with a nitrosylating agent under conditions suitable to nitrosylate the free thiol groups. To prepare an S-nitrated polymer, the polythiolated polymer is reacted with a nitrating agent under conditions suitable to nitrate the free thiol groups.

[0147] Suitable nitrosylating and nitrating agents are disclosed, for example, in Feelisch and Stamler, "Donors of Nitrogen Oxides", Methods in Nitric Oxide Research (John Wiley & Sons) (1996), edited by Feelisch and Stamler, the teachings of which are incorporated herein by reference. Suitable nitrosylating agents include acidic nitrites, nitrosyl chloride, compounds containing an S-nitroso group (S-nitroso-N-acetyl-D,L-penicillamine (SNAP), S-nitrosoglutathione (SNOG), N-acetyl-S-nitrosopenicillaminyl-S-nitrosopenicillamine, S-nitrosocysteine, S-nitrosothioglycerol, S-nitrosodithiothreitol, and S-nitrosomercaptoethanol), organic nitrites (e.g., ethyl nitrite, isobutyl nitrite, and amyl nitrite), peroxynitrites, nitrosonium salts (e.g., nitrosyl hydrogen sulfide), oxadiazoles (e.g., 4-phenyl-3-furoxanecarbonitrile), and the like. Suitable nitrating agents include organic nitrites (eg, nitroglycerin, isosorbide dinitrate, 5-isosorbide dinitrate, isobutyl nitrite, and isopentyl nitrite), nitronium salts (eg, nitronium tetrafluoroborate), and the like.

[0148] Nitrosylation with acidic nitrite can be carried out in aqueous solution using nitrite such as NaNO2, KNO2, LiNO2, in the presence of acid such as HCl, acetic acid, H3PO4, at a temperature of, for example, about -20°C to about 50°C, preferably 0°C. Generally, about 0.8 to about 2.0, preferably about 0.9 to about 1.1 equivalents of nitrosylating agent are used per thiol to be nitrosylated. Sufficient acid is added to convert all of the nitrite to nitrous acid.

[0149] Polythiolated polymers can be formed from polymers having multiple pendant nucleophilic groups, such as alcohols or amines, which can be converted to pendant thiol groups by methods known in the art and disclosed in Gaddell and Defaye, Angew. Chem. Int. Ed. Engl. 30:78 (1991) and Rojas et al., J. Am. Chem. Soc. 117:336 (1995), the teachings of which are incorporated herein by reference.

[0150] In one embodiment, the S-nitrosylated polymer is an S-nitrosylated polysaccharide. Polythiolated and perthiolated polysaccharides can be nitrosylated in the presence of a suitable nitrosylating agent, such as acidic nitrite or nitrosyl chloride, as described elsewhere herein.

[0151] It should be understood that agents capable of nitrosylating free thiols may also oxidize free thiols to form disulfide bonds. Thus, for example, treating a polythiolated polymer (e.g., a polythiolated polysaccharide, such as a polythiolated cyclodextrin) with a nitrosylating agent, such as acidified nitrite, nitrosyl chloride, or S-nitrosothiol, may result in the formation of a cross-linked S-nitrosylated polymer matrix. A "polymer matrix" is a molecule that includes a number of individual polymers that are connected and "cross-linked" by intermolecular bonds. Thereby, in some cases, the nitrosylating agent nitrosylates some of the thiols and also cross-links the individual polymers by causing the formation of intermolecular disulfide bonds. Such polymer matrices are encompassed by terms such as "S-nitrosylated polymers" and are within the scope of the present invention. When an excess of nitrosylating agent is used, and when the nitrosylating agent is of sufficient size, it can become incorporated or "entangled" within the polymer matrix through intermolecular disulfide bonds that bridge individual polymer molecules, thereby forming a complex between the polymer and the nitrosylating agent.

[0152] When 2 or more equivalents of a nitrosylating agent are used in the nitrosylation reaction relative to the free thiols in the polythiolated polysaccharide as described above, the S-nitrosylated polysaccharide, particularly the S-nitrosylated cyclized polysaccharide such as S-nitrosylated cyclodextrin, can form a complex with a suitable nitrosylating agent. In general, about 1.1 to about 5.0 equivalents, preferably 1.1 to about 2.0 equivalents of the nitrosylating agent are used to form the complex.

[0153] particle In some embodiments, when the particles containing NO-releasing functional groups are embedded within the polymer used to form the polymer coating, or when the medical device itself is a particle containing NO-releasing functional groups, the particles can be microparticles or nanoparticles. These particles can be formed from polymers containing NO-releasing functional groups, or can include small molecules containing NO-releasing functional groups.

[0154] As described below, in some embodiments, the conditions used to form the particles often include subjecting the polymer to conditions that decompose the NO-releasing functional group at least at some rate, for example by exposing the particles and their components to heat, light and / or a pH level below about 7. Thus, in some embodiments, the particles are prepared using polymers and / or compounds that have pendant functional groups that can be converted into NO-releasing compounds, and these groups are converted into NO-releasing functional groups after the particles are formed. In other embodiments, the particles are prepared using polymers that include NO-releasing functional groups, and it is understood that the particles may lose some of their NO-releasing capacity due to the decomposition of some of the NO-releasing functional groups during particle formation.

[0155] Microparticles are typically defined as particles between 0.1 and 100 μm in diameter, and nanoparticles are defined as particles between 1 and 100 nm in diameter. When used in drug delivery, the particles are preferably prepared from biodegradable polymers such as polylactic acid, polyglycolic acid, PLGA, polycaprolactone, polyanhydrides, and other polymers described elsewhere herein.

[0156] Microparticles or nanoparticles can be prepared through a wide range of methods. Representative techniques for preparing microparticles include emulsion-solvent evaporation (oil / water, water / oil and water / oil / water), phase separation (non-solvent addition and solvent partitioning), interfacial polymerization, spray drying, emulsion extraction processes, comminution techniques such as jet milling techniques, fluidization and solvent precipitation. The process often involves drying the particles to remove the solvent used in their preparation, and the drying process typically involves the use of sufficient heat to decompose NO-releasing functional groups and cause them to release nitric oxide early (i.e., before they are implanted in a patient).

[0157] Thus, in one embodiment, functional groups such as thiols and amines can be converted to NO-releasing functional groups after the particles are formed, thus largely avoiding this premature decomposition. Given their relatively large surface area, it is relatively easy to convert functional groups to NO-releasing functional groups.

[0158] The particles ideally comprise a biodegradable polymer. Many biodegradable polymer systems are generally recognized as safe for human use, providing a wide range of NO donor and biodegradable polymer combinations.

[0159] By creating controlled release biodegradable particles, the undesirable condition of implanted devices, particularly percutaneous implants such as ports, catheters, etc., leaving behind potentially harmful substances after being removed from the host is avoided.

[0160] Furthermore, this approach facilitates a wide range of hydrophobic particles into which NO-releasing donor compounds can be placed. One example of a desirable embodiment could be thiolactic acid (donor) doping inside biodegradable polycaprolactone or PLGA particles.

[0161] The process for preparing microparticles often involves forming a polymer solution, in which the active pharmaceutical agent may be present, and when the particles precipitate in the solution, the active pharmaceutical agent may become incorporated into the polymer.

[0162] In embodiments where the pH of the solution is relatively non-acidic (i.e., approximately 7.0 or greater) and the temperature at which the particles are formed and subsequently isolated is not sufficient to significantly degrade the NO-releasing functional groups, the NO-releasing functional groups on the polymer are not significantly degraded (i.e., less than a 10% loss in NO-releasing capacity during particle formation).

[0163] In embodiments where the pH of the solution is relatively acidic (i.e., less than about 6.9) and / or the temperature at which the particles are formed and subsequently isolated is sufficient to significantly degrade the NO-releasing functional groups, the NO-releasing functional groups on the polymer are not significantly degraded (i.e., less than 10% loss of NO-releasing capacity during particle formation). The temperature at which these NO-releasing functional groups degrade will vary depending on the particular functional group, but one of skill in the art can readily determine which functional groups can survive particle formation without significant decomposition of the NO-releasing functional groups without undue experimentation.

[0164] Nanoparticles can be prepared by a "wet" chemical process in which solutions of suitable compounds are mixed and otherwise processed to form an insoluble precipitate of the desired material. The size of the latter particles is controlled by choosing the reagent concentrations and solution temperatures, and by adding suitable inert agents that affect the viscosity and diffusion rate of the liquid. For different parameters, the same general process can yield other nanoscale structures of the same material, such as aerogels and other porous networks.

[0165] As with other particle preparation methods, the use of polymers and / or small molecules that have NO-releasing functional groups, or that have functional groups that can be subsequently converted to NO-releasing functional groups, to prepare nanoparticles is highly dependent on the temperature and pH of the solution in which the nanoparticles are prepared.

[0166] The nanoparticles formed in this manner can be separated from the solvent and soluble by-products of the reaction, typically by evaporation, precipitation, centrifugation, washing and / or filtration. Alternatively, if the particles are intended to be deposited on a medical device surface, the starting solution can be coated on that surface, for example by dipping or spin coating, and the reaction can be carried out in situ.

[0167] The wet chemistry approach allows for precise control of the chemical composition of the particles; various additives, such as active pharmaceutical ingredients, can be incorporated into the reagent solution and ultimately homogenously dispersed in the final nanoparticle product.

[0168] Nanoparticles can also be prepared from macro- or micro-scale particles by grinding in a ball mill, planetary ball mill, or other particle size reduction mechanism until a sufficient amount of them are in the nanoscale size range. The resulting powder can be air classified to extract the nanoparticles.

[0169] In some embodiments, the active pharmaceutical agent can be present in the coating either by blending it into the polymer coating solution or by incorporating it into the microparticles or nanoparticles.

[0170] small molecule Ideally, the small molecule has a molecular weight of less than 1,000 g / mol, more preferably less than 750 g / mol, and even more preferably less than 500 g / mol. Representative small molecules include compounds with S-nitroso groups. Examples include S-nitrosothiolacetic acid, S-nitroso-N-acetyl-D,L-penicillamine (SNAP), S-nitrosoglutathione (SNOG), N-acetyl-S-nitrosopenicillaminyl-S-nitrosopenicillamine, S-nitrosocysteine, S-nitrosothioglycerol, S-nitrosodithiothreitol, and S-nitrosomercaptoethanol.

[0171] Additional small molecules include organic nitrites (e.g., ethyl nitrite, isobutyl nitrite, and amyl nitrite), oxadiazoles (e.g., 4-phenyl-3-floxacarbonitrile), peroxynitriles, nitrosonium salts and nitroprussides, and other metal nitrosyl complexes (see, Feelisch and Stamler, "Donors of Nitrogen Oxides," Methods in Nitric Oxide Research (John Wiley & Sons) (1996), edited by Feelisch and Stamler).

[0172] The delivery time and volume of NO of the S-nitrosylated polymers described herein can be increased by incorporating small molecules that contain S-nitrosyl groups. The extent to which the delivery time and volume are increased varies with the volume of the small molecule.

[0173] Formation of Nitrosothiols and / or Diazeniumdiolates Nitrosation conditions are disclosed, for example, in C Zhang et al. Chem. Commun., 2017, 53, 11266-11277.

[0174] Nitrosylating agents that can be complexed with S-nitrosylated cyclic polysaccharides include those that have the size and hydrophobicity required to form an inclusion complex with the cyclic polysaccharide. An "inclusion complex" is a complex between a cyclic polysaccharide, such as a cyclodextrin, and a small molecule that is located in the cavity of the cyclic polysaccharide. The cavity size of a cyclic polysaccharide, such as a cyclodextrin, and the method of selecting an appropriate molecule for preparing an inclusion complex are well known in the art and can be found, for example, in Szejtli Cyclodextrins In Pharmaceutical, Kluwer Academic Publishers, pages 186-307 (1988), the teachings of which are incorporated herein by reference.

[0175] Nitrosylating agents that can be complexed with S-nitrosylated cyclic polysaccharides also include nitrosylating agents that have a sufficient size so that they can become incorporated into the polymer matrix structure of S-nitrosylated polysaccharides.As mentioned above, in certain instances, nitrosylation of polythiolated polymers can also result in crosslinking of individual polymer molecules by the formation of intermolecular disulfide bonds to obtain a polymer matrix.Suitable nitrosylating agents are of appropriate size so that they can be incorporated into this matrix.It should be understood that the size requirement is determined by the structure of each individual polythiolated polymer, and suitable nitrosylating agents can be routinely determined by those skilled in the art according to the specific S-nitrosylated polymer to be prepared.

[0176] Representative nitrating agents include organic nitrites and nitronium salts.

[0177] Polymers, particles and small molecules containing pendant nitrosothiol groups can be prepared by reacting a solution containing a polymer, particle or small molecule containing pendant (free) thiol groups with a nitrosylating agent under conditions suitable for nitrosylating the free thiol groups.

[0178] In one embodiment, the nitrosylating agent is selected from the group consisting of S-nitrosothiols, organic nitrites, oxadiazoles, peroxynitrites, nitrosonium salts, and metal nitrosyl complexes.

[0179] In one embodiment, the nitrosylating agent is an acidified nitrite. Examples of nitrite include sodium nitrite, potassium nitrite, calcium nitrite, and ammonium nitrite, any soluble nitrite that provides nitrate anion to the nitrosylating solution. Examples of acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and any strong acid that promotes the conversion of nitrate anion to a gaseous nitrosylating agent.

[0180] In some embodiments, the polymer, particle or small molecule is reacted with about 0.8 to about 2.0 molar equivalents, ideally about 0.9 to about 1.1 equivalents of acidified nitrite per mole of free primary thiol or secondary amine.

[0181] In another embodiment, the nitrosylating agent is nitrosyl chloride.

[0182] In some embodiments, the nitroxylation agent is a gas. In some aspects of these embodiments, an "effective amount" of a gaseous nitrosylation agent is an amount that results in nitrosylation of at least about 50%, preferably at least about 75%, and more preferably at least about 90% of the free primary thiol or secondary amine groups in the compound, particle, or polymer.

[0183] Preferably, a sufficient amount of gaseous nitrosylating agent is used to saturate the free primary thiol or secondary amine groups in the NO-bearing compound, particle, or polymer, i.e., all or substantially all (i.e., greater than 90%) of the primary thiol or secondary amine groups are nitrosylated to form nitrosothiols or diazeniumdiolates, respectively. Effective amounts range from about 0.8 atm to about 10 atm, preferably about 1 atm.

[0184] Representative nitrosylation conditions In one embodiment, a polymer containing primary thiol or secondary amine groups is dissolved in a mixture of an aqueous hydroxide solution, such as NaOH solution, and an aqueous nitrous acid solution, such as NaNO2, ideally about 0.5-1.5 equivalents per mole of free thiol or amine, and an acid, such as HCl, is added. If this process produces a precipitate, the precipitate can be collected and the acidic supernatant removed. The precipitate can be washed with water, such as deionized water, ideally with stirring, until the supernatant has a pH of about 6-8.

[0185] In another embodiment, a polymer containing primary thiol and / or secondary amine groups can be dissolved in a suitable solvent, for example a polar aprotic solvent such as DMF or DMSO. Nitrosyl chloride can be bubbled through the solution and the solvent removed under vacuum or a stream of inert gas such as nitrogen or argon to yield a polymer product containing an NO releasing group.

[0186] In yet another embodiment, a polymer containing primary thiol or secondary amine groups is dissolved in a hydroxide solution, such as a NaOH solution. A nitroso compound, such as D(+)-S-nitroso-N-acetylpenicillamine, can be added, which typically forms a precipitate. The precipitate can be collected and washed, typically until the supernatant has a pH of approximately 6-8.

[0187] Without wishing to be bound by any particular theory, it is believed that a portion of the nitrating or nitrosylating agent contacts the polymer, and if the agent is a gas, it contacts the polymer as well as the surface, and nitrates or nitrosylates functional groups that can be converted to NO-releasing groups. If the NO-releasing groups are formed before the medical device is manufactured, this generates NO2 or NO capacity of the polymer after manufacturing conditions are used that would otherwise result in a loss of NO-releasing capacity.

[0188] Formation of polymer coating Polymer coatings can be hydrophobic or hydrophilic. In some embodiments, it may be desirable to use hydrophobic coatings, especially when NO release is desired over an extended period of time, and when these coatings contain embedded particles or small molecules that contain NO-releasing functional groups.

[0189] By using a hydrophobic coating, physiological fluids can penetrate the coating quickly and cannot reach the embedded particles or small molecules. This can extend the time that NO can be released. In other embodiments, the coating is hydrophilic, which can help improve biocompatibility and reduce foreign body response, and can increase the rate at which NO can be released when exposed to physiological fluids compared to hydrophobic polymers. In various aspects of each of these embodiments, the polymer is biodegradable.

[0190] The particles embedded in or mixed with the polymer can be biodegradable and can be formed from the same or different polymer used to form the coating. If the particles are biodegradable, the NO release rate can be controlled by controlling the degradation rate of the polymer. With more of the particle surface exposed, more of the NO-releasing functional groups are exposed to physiological fluids, thereby releasing more NO.

[0191] In some embodiments, a hydrophobic polymer is used in the coating and hydrophilic or amphiphilic particles are embedded in the polymer coating. In other embodiments, a hydrophobic polymer is used in the coating and hydrophobic particles are embedded in the polymer coating. In yet other embodiments, a hydrophilic or amphiphilic polymer is used in the coating and hydrophobic particles are embedded in the polymer coating. In yet other embodiments, a hydrophilic or amphiphilic polymer is used in the coating and hydrophilic or amphiphilic particles are embedded in the polymer coating.

[0192] The loading of the particles in the polymer coating can vary, typically ranging from about 1 to about 50 weight percent, more typically from about 5 to about 45 weight percent, and preferably from about 10 to about 40 weight percent.

[0193] There are many ways in which coatings can be applied, each method has its own advantages and disadvantages, and not all methods are applicable to all devices or materials, although one skilled in the art will readily understand which coating methods are best for which devices.

[0194] Dip coating is a common process for coating medical devices. Dip coating typically involves surface preparation / cleaning, completely immersing the device in a coating solution, removing the device from the solution, drying and / or curing the coating using heat or light such as UV light, and post-treatment.

[0195] As discussed above with respect to particle formation, where the full / partial immersion, drying and / or curing steps may result in significant degradation of NO-releasing functional groups if present on the polymer and / or in the particles or small molecules embedded in the polymer when the coating is applied, in some embodiments functional groups such as primary thiol groups and secondary amine groups are present in the polymer, particle or small molecule and are converted to NO-releasing functional groups after the coating is applied, thereby avoiding decomposition of the NO-releasing functional groups while the coating is applied and / or cured.

[0196] Spray coating can also be used, which typically involves using a nozzle and driver to atomize the coating solution and apply it as a mist to the medical device surface, and ultrasonic transducers can be used to control the spray droplet size, which affects the thickness and quality of the coating.

[0197] Reel-to-reel coating can be used in certain embodiments, but typically cannot be used for small, complex devices. A reel of wire or film is unwound and runs through a reservoir of coating liquid and into an oven for drying or curing before being wound onto a second reel. This approach can be used to prepare the tapes and monoliths described herein.

[0198] As with dip-coating, in embodiments where the drying and / or curing process is likely to significantly degrade NO-releasing functional groups present on the polymer used in the coating, or in particles or small molecules mixed or embedded in the polymer, it may be desirable to convert functional groups such as primary thiols or secondary amines to NO-releasing groups after the coating has been applied.

[0199] Robotic coating can be applied to complex shapes and can accommodate continuous systems. Small nozzles are controlled by the robot to trace along posts and other structures. The viscosity of the coating fluid can be programmed as needed.

[0200] Spin coating is another common technique for applying thin films to substrates. It can be quickly and easily produced uniform films with thicknesses ranging from a few nanometers to a few microns, but is typically only used to coat flat surfaces.

[0201] Full dip coating is a relatively simple process. Many devices require only 30 seconds of full immersion to be fully functional and often do not require curing. Full dip coating is commonly used to coat medical devices.

[0202] In one embodiment, a medical device, for example an electrode or stent used in a continuous glucose monitor, is coated with a polymer that includes an NO-releasing functional group, and in certain aspects of this embodiment, includes a functional group, such as a primary thiol or a secondary amine, that can be converted to an NO-releasing functional group after the coating process is complete.

[0203] In another embodiment, the medical device is coated with a polymer that includes embedded particles or small molecules that include NO-releasing functional groups, and in certain aspects of this embodiment, include functional groups that can be converted to NO-releasing functional groups after the coating process is complete, such as primary thiols or secondary amines. In other embodiments, the polymer and embedded particles and / or small molecules include NO-releasing groups, or in certain embodiments of these embodiments, functional groups that can be converted to NO-releasing groups after the coating process is complete.

[0204] In one aspect of these embodiments, the device is coated with a polysaccharide containing pendant nitrosothiol groups, or pendant thiol groups that are then converted to NO-releasing groups, thereby forming S-nitrosylated cyclodextrins, starches, dextrins, dextran, glycosaminoglycans, cellulose, and the like.

[0205] In one embodiment, the medical device is coated with a polymer solution containing a polysaccharide containing multiple nitrosothiol groups (i.e., a polythiolated polysaccharide that is contacted with a nitrosylating (or nitrosating) agent under conditions suitable to nitrosylate (or nitrate) free thiol groups before or after the coating process is completed, resulting in the formation of an S-nitrosylated (or S-nitrosated) polysaccharide).

[0206] In one aspect of this embodiment, the polymer coating solution comprises a polar aprotic solvent, such as dimethylformamide (DMF) or dimethylsulfoxide (DMSO). The coating solution is applied to all or a portion of the device using any of the conventional methods for applying coating solutions that are appropriate for medical devices. The coating can then be dried in a vacuum, an oven, or under a flow of an inert gas, such as nitrogen or argon.

[0207] In embodiments in which the coating is capable of being subsequently converted to NO-releasing functional groups, the coated device can then be subjected to appropriate conditions to convert the pendant thiol or amine groups in the coating to NO-releasing groups.

[0208] In one aspect of these embodiments, the polymer solution includes particles of hydrophobic polymers such as polyurethanes and hydrophilic or hydrophobic polymers, where the particles include NO-releasing functional groups such as nitrosothiols or diazeniumdiolates, or include functional groups such as primary thiols or secondary amines that are subsequently converted to NO-releasing functional groups such as nitrosothiols or diazeniumdiolates. The coating solution is applied to the medical device or a portion of the medical device, and the coating is cured. In embodiments where the coating can subsequently be converted to NO-releasing functional groups, the coated device can then be subjected to appropriate conditions to convert the pendant thiol or amine groups in the coating to NO-releasing groups.

[0209] In any of these embodiments, the coating can optionally include dyes, pigments, and / or light stabilizing compounds that inhibit the decomposition of the NO-releasing group when the coated medical device is exposed to light. In another aspect, the spray, tape, monolith, etc. can also include such dyes, pigments, and / or light stabilizing compounds.

[0210] Monolith / Film / Tape In various embodiments, the tape or film is formed from a biodegradable polymer that contains one or more pendant NO-releasing groups and / or contains embedded particles or small molecules that contain NO-releasing groups. In some aspects of this embodiment, the tape / film coats all or a portion of the medical device.

[0211] The tape or film can be physically or chemically attached to the medical device, such as an implant. If the tape or film is chemically attached, it preferably comprises a biocompatible adhesive, preferably a biodegradable adhesive. Such adhesives are well known to those skilled in the art. One-part and two-part epoxy and silicone biocompatible adhesives can be used, which can be a variety of light-cured materials, epoxy-polyurethane blends and cyanoacrylates. In one embodiment, the adhesive is a biocompatible and biodegradable polyurethane adhesive. In another embodiment, the adhesive is poly(glycerol sebacate acrylate) (PGSA).

[0212] Sprayable formulations The sprayable formulations described herein include a mixture of chemicals that form a biodegradable polymeric film on at least one surface or portion of the implant to which it is applied, in one embodiment, the polymeric film conforms and adheres to the covered area on the implant.

[0213] The formulation comprises a biodegradable biocompatible polymer, a solvent for the polymer that has a boiling point of less than about 100°C, preferably less than about 85°C, more preferably less than about 70°C, and a propellant that can be a gas or a volatile liquid. The polymer can be any of the polymers described elsewhere herein, including those that have pendant NO-releasing functional groups, and in one embodiment is a hydrophobic polymer. Ideally, the polymer has relatively low cytotoxicity. In some embodiments, the polymer does not have pendant NO-releasing groups, and in these embodiments, the sprayable formulation comprises particles with NO-releasing groups or small molecules with pendant NO-releasing groups.

[0214] The spray formulation has the following characteristics: (1) low viscosity or liquid-like properties when sprayed, allowing for easy application to the desired area on the implant to be applied; (2) minimal washout by body fluids and activation of NO-releasable functional groups only when the medical device is implanted; (3) exceptional adhesive strength, especially in the presence of blood and / or other body fluids; (4) the ability of the implant to withstand the mechanical loads it will be subjected to after implantation; (5) minimal inflammatory response, and (6) Biodegradability.

[0215] In addition to these properties, the films formed by the sprayable formulations release nitric oxide over time, which minimizes microbial contamination often associated with surgery, promotes wound healing, increases vascularization around the implant, and minimizes scar formation. The sprayable formulations described herein provide such nitric oxide release.

[0216] In one embodiment, the biodegradable polymer in the sprayable formulation contains one or more of (meth)acrylate functional groups, or cyanoacrylate, or a combination of albumin and glutaraldehyde, or contains poly(ethylene glycol) (PEG) blocks, or contains polyurethane or fibrin.

[0217] Cyanoacrylates belong to a class of monomers consisting of alkyl esters of 2-cyanoacrylic acid. Representative cyanoacrylates include methyl, ethyl, n-butyl, isobutyl, isohexyl, and octyl cyanoacrylate. Cyanoacrylates are capable of adhering to most implant surfaces.

[0218] Fibrin can be obtained, for example, from pooled human plasma.

[0219] If cyanoacrylates (CA) or fibrin are used, they may not have all or even most of the desired properties for a sprayable formulation, although nitric oxide releasing particles or small molecules can be blended with these materials, which at least may have beneficial properties related to nitric oxide release.

[0220] In one embodiment, the sprayable formulation contains a combination of purified bovine serum albumin (BSA) and glutaraldehyde, which polymerizes in situ at the application site within 30 seconds and achieves full strength within 2 minutes.

[0221] In another embodiment, the sprayable formulation includes a hyperbranched polyurethane with isocyanate end groups and lysine. The amine groups in the lysine crosslink with the isocyanate groups resulting in adhesive crosslinking within 25 minutes.

[0222] PEG-based polymers can also be used. These polymers can be polyethylene glycol-based synthetic hydrogels, including block copolymers containing one or more polyethylene glycol blocks and one or more PLGA blocks, also containing carbonate linkages, and containing (meth)acrylate end caps. The presence of PEG blocks in the polymer can minimize tissue adhesion to implanted medical devices. The film is degradable by the PLGA blocks. It can also be attached to the implant using the (meth)acrylate end groups. In one embodiment, the sprayable formulation includes PEG-co-trimethylene carbonate-co-lactide with acrylated end groups, and Eosin Y is added as a component to generate free radicals that react with light to polymerize the polymer in situ after the formulation is applied to the medical device.

[0223] In another embodiment, polymers including human serum albumin (HSA) and di-PEG-succinimidyl succinate, which are capable of being crosslinked together and sprayed, are applied using a dual nozzle sprayer to avoid mixing of the components prior to application, thereby allowing them to harden in situ by crosslinking upon application.

[0224] In another embodiment, sprayable formulations include tetra-PEG-succinimidyl ester and trilysine amine, which are applied using a dual nozzle sprayer and can crosslink upon application.

[0225] In one embodiment, the sprayable formulation is a block copolymer comprising one or more polyalkylene glycol blocks, such as polyethylene glycol blocks, and one or more degradable blocks.

[0226] In some embodiments, the degradable blocks are formed from any suitable combination of degradable monomeric units, such as lactic acid, glycolic acid, hydroxybutyric acid, caprolactone, carbonate, and the like, and in some embodiments, they are peptides such as trilysine or other short chain (i.e., less than 25 monomeric units) peptides containing three or more lysine monomeric units, or proteins such as albumin.

[0227] In some embodiments, the polymer in the sprayable formulation also contains vinyl groups (such as (meth)acrylate groups) that can be polymerized via free radical polymerization. In other embodiments, the sprayable formulation is a two or more component system, where one component contains functional groups that can crosslink with functional groups on another component.

[0228] In one embodiment, a block of polyalkylene glycol, such as polyethylene glycol, contains functional groups that crosslink with different functional groups on the degradable block, and one of skill in the art will understand which functional groups are capable of crosslinking with other functional groups under physiological conditions.

[0229] In one aspect of this embodiment, the degradable block comprises one or more monomer units containing pendant thiol or amine groups, which can be modified to form nitrosothiols, diazeniumdiolates, or other NO-releasing groups before the adhesive is applied. In this embodiment, it is important that the nitrosothiols, diazeniumdiolates, or other NO-releasing functional groups do not interfere with the crosslinking chemistry. In another embodiment, the surgical adhesive is blended with particles or small molecules containing NO-releasing functional groups. A combination of these approaches can be used.

[0230] The polymers can be modified to contain monomeric units with pendant thiol or amine groups and converted to nitrosothiol, diazeniumdiolate, or other NO-releasing groups, resulting in NO release after the sprayable formulation is applied and the resulting film coating is exposed to physiological fluids. Alternatively, the polymers in the sprayable formulation can be blended with particles or small molecules that contain NO-releasing functional groups.

[0231] Optional Additional Active Agents The coating, or tape, monolith and / or film formed from applying the sprayable formulation to the medical device, can also release additional substances over time that suppress the foreign body response by methods other than local NO release. These substances include VEGF or VEGF promoters, TNF-α and / or β inhibitors including anti-TNF-α and / or β antibodies, anti-inflammatory compounds such as halofunginone, antibacterial compounds, dexamethasone and monobutyrin. These additional substances can further prevent or minimize the foreign body response.

[0232] others In one embodiment, the particles containing biodegradable polymers encapsulate NO donor moieties, such as polymers or small molecules that contain pendant NO-releasing functional groups. This is advantageous for several reasons. Many biodegradable polymer systems are generally accepted as safe for human use. This allows for a wide range of combinations of NO donors and biodegradable polymers.

[0233] By creating controlled release biodegradable particles, the undesirable condition of a device such as a glucose sensor leaving behind potentially harmful substances after it is removed from the host is avoided.

[0234] Moreover, this approach facilitates a wide range of hydrophobic particles into which NO-releasing compounds can be placed. One example of an NO-releasing compound is thiolactic acid, where the thiol group has been converted to a nitrosothiol group, and this modified thiolactic acid has been embedded within biodegradable particles, such as biodegradable polycaprolactone or PLGA particles.

[0235] Applications include external hydrophilic coatings for analyte sensors, such as glucose sensors, or in the formulation of surgical adhesives. In the first example, lowering the FBR on glucose sensors extends their clinically useful life. In the second example, NO improves healing rates and reduces scar tissue formation, which may be desirable since scar tissue generated after a successful surgical outcome can often lead to long-term secondary complications.

[0236] Medical Devices In some embodiments, the medical device is a percutaneous implant comprising a coating comprising a biocompatible polymer, optionally a biodegradable polymer, and optionally comprising embedded particles. Exemplary percutaneous implants include transcutaneous glucose monitors, catheters including urinary catheters and chemotherapy venous ports / catheters (e.g., indwelling ports), fluid drainage devices (drains), drug delivery devices, blood sampling devices, percutaneously implanted neurostimulator electrode arrays, tracheostomy ports, abdominal wall opening ports, and any device that pierces the skin for the purpose of reaching fluids at the skin surface or beneath a body cavity.

[0237] In other embodiments, the medical device is a tape, stitch, adhesive, monolith or tissue scaffold, or other device that is applied to a patient rather than implanted, or a device that can be used to grow cells, tissues or organs ex vivo.

[0238] In some embodiments of these devices, the device comprises a NO-releasing coating comprising a polymer with pendant NO-releasing groups, in other embodiments the device comprises a coating that incorporates a particle or small molecule that comprises a NO-releasing group, and in yet other embodiments the coating also comprises a polymer with pendant NO-releasing groups or also comprises an embedded particle or small molecule that comprises a NO-releasing group.

[0239] In various aspects of these embodiments, the NO-releasing coating can be formed from a biocompatible polymer, which can be a biodegradable polymer that optionally includes pendant NO-releasing groups, such as diazeniumdiolates and / or nitrosothiol (SNO) groups, and a dye, pigment, or light-stabilizing compound. Before implantation, the dye, pigment, or light-stabilizing compound minimizes the degradation of the NO-releasing group due to exposure to light. After implantation, the NO-releasing group on the polymer surface is exposed to biological fluids. This causes the group to release nitric oxide. The biocompatible, optionally biodegradable polymer can be hydrophilic or hydrophobic. If the polymer is a biodegradable polymer, it may be preferable for the polymer to be hydrophobic to delay degradation and extend the release of nitric oxide.

[0240] In another aspect of this embodiment, the coating comprises embedded particles, such as microparticles or nanoparticles, prepared from small molecule and / or polymeric compounds that contain nitrosothiol groups, which may or may not contain NO-releasing groups, such as nitrosothiol groups and / or diazeniumdiolate groups.

[0241] In yet another aspect of this embodiment, the coating may include small molecule and / or polymeric compounds that contain nitrosothiol groups, which are not formed into microparticles or nanoparticles, but rather are simply blended into the polymer.

[0242] The coating can be applied, for example, by dip coating, spraying, brushing, etc. The second coating minimizes degradation of the NO-releasing group. Ideally, the coating is permeable to physiological fluids when the device is implanted so that nitric oxide can be released from the coating.

[0243] In various aspects of this embodiment, the coating can be formed from a biocompatible, optionally biodegradable polymer that includes pendant NO-releasing groups, such as diazeniumdiolate and / or nitrosothiol (SNO) groups.

[0244] After implantation, the NO releasing group on the polymer surface, such as nitrosothiol group, is exposed to hydrophilic biological fluid. This allows the group to release nitric oxide. As the polymer surface is biodegraded, new polymer surface is continuously exposed. Depending on the hydrophobicity of the polymer, once the polymer is exposed to moisture, both the internal NO releasing group and the surface NO releasing group can deliver their NO payload, or the internal nitrosothiol group can be protected and the polymer can continuously release nitric oxide when it is biodegraded. Thus, nitric oxide can be released until the coating is completely biodegraded. When the polymer is a hydrophobic polymer, whether the pendant NO releasing group is present on the polymer or on a particle embedded in the polymer, this can result in extended nitric oxide release compared to hydrophilic polymers.

[0245] In some embodiments, the device includes a coating formed from a biocompatible polymer, optionally a biodegradable polymer, that includes pendant NO-releasing groups, such as diazeniumdiolate and / or nitrosothiol (SNO) groups. After implantation, the NO-releasing groups on the polymer surface are exposed to biological fluids, whereupon they release nitric oxide.

[0246] In various embodiments, the polymer and / or compound contain nitrosothiol groups and are capable of releasing nitric oxide over an extended period of time, such as, for example, one week, two weeks, three weeks, or one month or more.

[0247] Degradation time can be controlled by judicious selection of the monomers used to prepare the biodegradable polymer, as well as the crystallinity, molecular weight and hydrophobicity. For example, polyglycolic acid tends to biodegrade faster than polylactic acid, and copolymers of lactic acid and glycolic acid can be prepared from these monomers in various ratios to control degradation time.

[0248] In yet other embodiments, the device is sprayed with a NO-releasing formulation described herein, or a NO-releasing tape or monolith is applied to the device.

[0249] Percutaneous implant In some embodiments, the medical device is a percutaneous implant, where all or a portion of the implant is formed from, sprayed with or coated with a nitric oxide releasing material, or a nitric oxide releasing tape or monolith is applied to the implant. Percutaneous implants include, for example, transcutaneous glucose monitors, catheters / ports including urinary catheters and chemotherapy intravenous ports / catheters (e.g., indwelling ports), as well as open ports such as tracheostomy ports and abdominal wall open ports, fluid evacuation devices (i.e., drains), drug delivery devices, percutaneously implanted neurostimulator electrode arrays, blood sampling devices, and any other device that pierces the skin for the purpose of reaching bodily fluids below the skin surface or within a body cavity.

[0250] Catheters, ports, fluid drainage devices (i.e., drains), drug delivery devices, and blood collection devices can be modified by coating with a polymeric coating described herein, adhering a tape or monolith, or spraying with a sprayable formulation described herein, where the coating, tape, monolith, or spraying onto the formulation releases nitric oxide upon implantation. The release of nitric oxide can inhibit bacterial growth in and around the device and inhibit foreign body responses to the device. As an example, urinary catheters can cause urinary infections, and the release of nitric oxide from the catheter can minimize the chance of infection.

[0251] Fluid drainage devices (e.g., drains) can be used to drain, for example, ascites, or fluid that accumulates around the patient's heart, or fluid that accumulates around a surgical site, and the release of nitric oxide minimizes microbial contamination and promotes wound healing.

[0252] Drug delivery and blood collection devices typically include tubes that are inserted into a patient for the purpose of delivering drugs over an extended period of time or for repeated blood collection. Examples include ports, such as chest ports. Tissues surrounding these ports can be subject to infection and / or foreign body responses, which can be minimized using the coatings, tapes, monoliths, or sprayable formulations described herein.

[0253] Transcutaneous glucose monitor Traditional glucose monitoring systems collect a drop of blood onto a strip and measure insulin levels when the strip is inserted into the system. This type of device is used periodically to ensure that the "flash" glucose monitoring system is accurately calibrated. This can be important over time as the body develops a foreign body response to the implanted electrodes.

[0254] "Flash" glucose monitoring systems typically include a wireless transmitter for wirelessly transmitting data regarding the patient's insulin levels to a display. Conventional glucose monitoring systems do not provide a method for countering the foreign body response, and the glucose monitoring system described herein, which does provide a method for countering the foreign body response.

[0255] The system also typically includes a surface that adheres to the user's skin and includes an injectable biosensor. The CGM described herein preferably uses electrochemical biosensors because they can be miniaturized and offer high selectivity and sensitivity governed by the specific biocatalysis of immobilized enzymes.

[0256] The biosensor measures glucose levels, and these levels are typically displayed on a display, such as the screen of a smartphone. Glucose levels can be measured, for example, using a series of known chemical reactions: Glucose is oxidized to glucanolactone by glucose oxidase. Oxygen is consumed and hydrogen peroxide is produced. Ag / AgCl electrodes can determine oxygen consumption and / or hydrogen peroxide production, and these levels can equate to the amount of glucose oxidized. This then provides a measurement of the glucose level.

[0257] Enzyme-based sensors measure the rate of glucose oxidation via changes in oxygen or hydrogen peroxide concentration upon reaction of glucose with a glucose-specific enzyme (e.g., GOx or GDH). In some embodiments, the enzyme is immobilized on an electrode surface. The enzyme is reduced upon conversion of glucose to gluconolactone. Ambient oxygen promotes the conversion of the reduced enzyme to its oxidized form with the concomitant production of hydrogen peroxide.

[0258] Glucose concentration correlates with the amperometric signal obtained from either the electrochemical oxidation of the produced hydrogen peroxide or the reduction of the consumed oxygen. Although enzyme-based electrochemical glucose biosensors are characterized by high selectivity and sensitivity due to their enzymatic nature, the dynamic range of such sensors is limited by the availability of the co-substrate (i.e., oxygen). An external diffusion-limiting membrane is therefore utilized to control the range and eliminate oxygen depletion, although the sensor response is slightly delayed. In addition, the working electrode potential required to monitor hydrogen peroxide (i.e., about +0.6 V vs. Ag / AgCl) also oxidizes electroactive endogenous species (e.g., ascorbic acid and acetaminophen), creating high current densities. To address these shortcomings, second-generation electrochemical glucose biosensors utilize an electron mediator (e.g., Os(4,4-dimethoxy-2,2'-bipyridine)2Cl+ / 2+) “connected” to the enzyme on a hydrophilic polymer matrix (e.g., poly(vinylpyridine) or poly(vinylimidazole)). Such mediators can shuttle electrons from the redox center of the enzyme to the electrode surface, allowing the applied electrode potential to be lowered, and the sensor response is then independent of co-substrates and interferences.

[0259] However, other glucose measurement techniques using injected biosensors can also be used and are within the scope of the present invention. For example, in one embodiment, the CGM uses a non-enzymatic electrochemical glucose sensor rather than an enzymatic electrochemical glucose sensor. In one aspect of this embodiment, glucose is measured directly via direct electrooxidation at a high surface area (i.e., porous) platinum electrode or through potentiometric detection in response to the pKa change of a conducting polymer.

[0260] Injectable ("transdermal") glucose sensors can include potentiostats, Ag / AgCl electrodes, and Pt-Ir electrodes. The Pt-Ir electrodes are typically coated with multiple polymer layers, including an outer diffusion-limiting layer, an enzyme (GOx) layer, and an inner selective layer. The portion of the CGM that covers the user's skin contains the sensor array, electronic module, battery, and telemetry / transmission portal.

[0261] In one embodiment of a subcutaneous continuous glucose monitoring (CGM) device, the device includes an enzyme-immobilized amperometric biosensor. The device includes a disk-shaped sensor with a titanium housing. The device includes a sensor array, an electronic module, a battery, and a telemetry / transmission portal. These components are typically found in transdermal CGMs as well, but because only the biosensor is implanted, they are found in the portion of the CGM that covers the user's skin.

[0262] A display for displaying the glucose level wirelessly transmitted from the "Flash" glucose monitoring system can receive signals from the telemetry / transmission portal.

[0263] In use, the glucose monitor is applied to the skin and the electrodes penetrate the skin to a depth of about 3 to 8 mm, more typically about 4 to about 7 mm. The electrodes include a coating that releases nitric oxide at or near the surface of the electrode.

[0264] For a transdermal or subcutaneous glucose monitor, the foreign body response over time is shown in FIG. 5. Over the first 5 days, the implanted biosensor undergoes protein absorption and matrix deposition, with neutrophils, mast cells, and blood vessels forming around the sensor. This is considered an acute inflammatory response to the implanted biosensor. Between 5 and 21 days after implantation, the sensor undergoes monocyte adhesion, as well as macrophage fusion and differentiation. This is considered a chronic inflammatory response. From this point on, the sensor undergoes FBGC (foreign body giant cell) formation, as well as fibroblast infiltration and collagen formation. This results in the formation of granulation tissue and fibrous encapsulation of the implanted biosensor.

[0265] A foreign body response after implantation could lead to a sudden drop in local pH to as low as 3.6, disrupting biosensor performance, since GOx activity is pH dependent. Release of nitric oxide in close proximity to the glucose sensor can minimize the foreign body response, thereby minimizing the concomitant disturbance of the pH sensor by lowering the local pH level to a level that deteriorates sensor performance.

[0266] Various embodiments of CGMs and devices for use with CGMs are described in more detail below. Provided below are descriptions that should be understood as representative, and thus non-limiting, of representative examples of CGMs that emit light to inhibit, reduce or prevent a foreign body response.

[0267] In one embodiment, a transdermal continuous glucose monitor is disclosed that is modified to enable a reduced foreign body response when a biosensor is injected into a user's skin.

[0268] Modifications include providing coatings that release exogenous nitric oxide at appropriate local concentrations and for sufficient duration, antimicrobial effects to reduce collagen production, increased vascularization around the implant, and other biological effects to reduce the foreign body response to the implanted sensor.

[0269] As mentioned above, a transdermal CGM includes a portion that is adhered to and covers the skin, which includes a biosensor that is injected under the skin and electrical components that read information about glucose levels and transmit this information to a display, either by wired or wireless connection. In addition to the biosensor, the components of a CGM typically include a sensor array, an electronic module, a battery, and a telemetry / transmission portal. Means for wirelessly transmitting signals from a CGM to a display are well known in the art and will not be described further herein.

[0270] Glucose sensor coating In the transdermal glucose monitors described herein, the glucose sensor is at least partially coated with a polymeric coating described herein that releases nitric oxide over time to inhibit foreign body responses to the implanted glucose sensor and to help inhibit bacterial growth around the sensor.

[0271] A coating is a biocompatible coating. As used herein, a sensor coating is "biocompatible" if it optimizes the clinical relevance of the sensor, avoids any negative local and systemic effects, and elicits the most appropriate local tissue response adjacent to the implant.

[0272] In addition to the biodegradable coating materials mentioned above, exemplary biocompatible coatings for glucose sensors include polyurethanes, Nafion, polyethylene glycol, silicones, zwitterionic polymers, polyesters including polyhydroxy acids such as PLA, PGA, and PLGA, polyglycolic lactic acid (PGLA), polysulfone (PSU), gelatin, polyvinylpyrrolidone, and copolymers thereof, which also contain pendant SNO groups, embedded particles containing SNO-containing compounds, or in some embodiments, small molecules containing SNO groups blended into the polymer coating or particles.

[0273] If the coating is biodegradable, the particles can emerge from the coating over time as the coating degrades, and the particles can release nitric oxide upon the SNO-containing compound coming into contact with physiological fluids.

[0274] The coated and / or embedded particles may also include one or more additional compounds capable of suppressing a foreign body response. Representative examples include, for example, VEGF or compounds that promote VEGF, TNF-α and / or β inhibitors, including anti-TNF-α and / or β antibodies, anti-inflammatory compounds such as halofunginone, dexamethasone, and monobutyrin, and anti-bacterial compounds.

[0275] Molecular interference with FBR can include local immunosuppression with corticosteroids. Activation of leukocytes and fibroblasts can be attenuated using anti-transforming growth factor beta antibodies or halofunginone. Vascular development can be stimulated using pro-angiogenic vascular endothelial growth factor (VEGF) or other angiogenic compounds to improve perfusion and performance of bioactive implants.

[0276] Blood glucose quantification In some embodiments, the biosensor uses an enzymatic approach, such as GOx, to measure glucose oxidation, oxygen consumption, and / or hydrogen peroxide formation as a method of quantifying blood glucose levels.

[0277] Biosensors must be sensitive to differences in tissue concentrations of oxygen and glucose, and various coating layers on the portion of the biosensor carrying the working electrode have been developed to help control the permeability of glucose and / or oxygen to provide a more reliable reading.

[0278] In some embodiments, biocompatible coatings are applied to the biosensor, and in some aspects of these embodiments, compounds that inhibit the foreign body response are eluted from these coatings.

[0279] These approaches are described in more detail below.

[0280] Nonenzymatic electrochemical glucose sensor In one embodiment, the CGM uses a non-enzymatic electrochemical glucose sensor rather than an enzymatic electrochemical glucose sensor. In one aspect of this embodiment, glucose is measured directly via direct electrooxidation at a high surface area (i.e., porous) platinum electrode or through potentiometric detection in response to the pKa change of a conducting polymer.

[0281] Implantable Microdialysis Probe In another embodiment, the CGM uses an implantable microdialysis probe rather than an enzymatic electrochemical glucose sensor. Glucose in the interstitial fluid is measured by withdrawing the dialysate. Microdialysis avoids direct implantation of a sensor, but glucose measurements (i.e., collections) have historically been irregular in vivo due to foreign body responses. The implantable microdialysis probe is improved by including the ability to emit nitric oxide over time, which minimizes the foreign body response, thereby improving the technology.

[0282] Needle-type transdermal microsensor Needle-type transdermal microsensors amperometrically monitor hydrogen peroxide production as a measure of glucose concentration. The sensing cavity generally consists of a Pt-Ir wire working electrode coated with three functional layers: an inner selective layer, an enzyme layer, and an outer membrane. A silver / silver chloride (Ag / AgCl) wire is wrapped around the working electrode and serves as both a pseudo reference electrode and a counter electrode. Such sensors are typically characterized by a short stabilization period (e.g., 2-4 hours) compared to subcutaneous glucose sensors, and the device penetrates a dermal opening that carries the risk of co-infection. In some cases, frequent calibration (e.g., twice per day) may be required even after the stabilization period due to changes in the sensor response. Furthermore, the transdermal nature of the device generates additional forces on the sensor, such as mechanical motion, which may result in even greater inflammation. Minimization of foreign body responses, especially inflammatory responses, may be useful in minimizing the need for calibration.

[0283] Due to foreign body responses, sensor lifetime is typically 5-14 days, at which point the biosensor must be replaced. Patient compliance in this regard remains poor. By using the nitric oxide-releasing polymers described herein, sensor lifetime can be increased to 8-31 days, e.g., 14-31 days or more.

[0284] Improved selectivity using polymer coatings / selectively permeable films Sensor accuracy is important for compliance. However, many substances are electroactive at the electrode potentials used to oxidize hydrogen peroxide and can therefore interfere with the sensor response. Selectively permeable membranes that operate via size exclusion and / or electrostatic repulsion mechanisms are often used to improve selectivity. The composition of such membranes must be taken into account when considering biocompatibility, as the polymers may come into contact with tissues and ultimately affect the foreign body response.

[0285] The range of polymeric materials being evaluated as effective permselective films / coatings for electrodes includes cellulose acetate, Nafion, electropolymerized membranes (eg, polyphenols) and multilayer hybrids of these polymers.

[0286] Polyphenol-permselective membranes can be charge polymerized within the enzyme layer in a controllable manner, resulting in films with self-regulating thickness (10-100 nm). This simple approach is therefore very attractive for reducing interferences. In some cases, the membranes also exclude surface-active macromolecules (i.e., proteins and platelets) and protect the surface from biofouling.

[0287] The use of a mediator to shuttle electrons between the enzyme and the electrode can also minimize the effect of interfering species by lowering the working potential required to oxidize hydrogen peroxide. Exemplary redox mediators include ferrocene and osmium complexes, quinone compounds, metal phthalocyanines, carbon nanotubes, and conducting polymers.

[0288] Oxygen Dependence Electrochemical detection of hydrogen peroxide requires oxygen, a cofactor for the glucose oxidase reaction (GOx). The oxygen concentration in interstitial fluid is approximately 10 times lower than the glucose concentration in interstitial fluid, resulting in an "oxygen starvation" condition. This is typically addressed by incorporating an external diffusion-controlling membrane into the biosensor / electrode.

[0289] Low concentrations of oxygen present problems with the biosensor response to glucose (especially the dynamic range) due to a stoichiometric imbalance between the two cofactors. Oxygen depletion can be mitigated by using polymer membranes that reduce glucose diffusion or utilize alternative electron mediators.

[0290] In some embodiments, similar membranes are used to eliminate polar interference and increase the oxygen / glucose permeability ratio. Exemplary polymers include polyurethanes, Nafion, silicone elastomers, polycarbonates, and layer-by-layer polyelectrolytes.

[0291] Sensor performance problems due to changing oxygen levels are exacerbated by the foreign body response, which results in local consumption of oxygen and glucose by inflammatory cells near the sensor. Oxygen diffusion to the sensor decays exponentially after sensor implantation due to changes in tissue permeability. Thus, local release of nitrate in close proximity to the tissue surrounding the biosensor reduces these performance problems and allows the biosensor to be used for relatively long periods of time before it needs to be replaced.

[0292] Sensor component stability and degradation In vivo failure of the sensor components can be categorized as follows: 1) enzyme instability and leaching, 2) membrane degradation and delamination, and 3) electrode passivation. Enzyme activity begins to decrease immediately due to both polymer entrapment and exposure to reactive oxidizing species by sensor actuation and FBR (exposure to hydrogen peroxide and other reactive radicals).

[0293] Effective immobilization strategies can help ensure enzyme stability, including cross-linking the enzyme with bovine serum albumin (BSA) or glutaraldehyde, entrapment of the enzyme within a polymer matrix (e.g., hydrogels and sol-gel derived materials) with or without covalent structures, incorporation of the enzyme into electropolymerized conducting polymers such as polypyrrole, and immobilization of the enzyme onto an electrode surface by electrostatic interactions generated by a polyelectrolyte.

[0294] Nevertheless, even properly immobilized enzymes inherently lose activity over time, primarily due to loss of the non-covalently bound FAD cofactor, although inactivation by endogenously produced hydrogen peroxide from the oxidase reaction also contributes to the loss of activity. High glucose concentrations and the requirement for an adequate sensor signal imply fast production of peroxide and concomitant enzyme inactivation.

[0295] Sensors typically include films or membranes used as sensing layers, barrier membranes and / or biocompatible layers. These materials are subject to degradation due to foreign body responses and oxidative attacks such as those caused by calcification and delamination. When the films peel off or degrade, sensor instability or failure occurs automatically. Electrode fouling (often electrode passivation) is another source of sensor instability and occurs when small molecules diffused after perforation of the sensor membrane come into contact with the electrode surface.

[0296] The use of coatings that provide low concentrations of nitric oxide as described herein can minimize the adverse effects caused by the foreign body response.

[0297] In vivo calibration Because the analytical performance of CGM sensors changes dramatically upon implantation, it is necessary to define and evaluate sensor accuracy. Traditionally, the in vivo accuracy of such devices is evaluated using a numerical value or percentage of accuracy. Current numerical and clinical accuracy measures for CGM include linear regression or correlation coefficient, mean (or median) absolute deviation and relative absolute difference (MAD and MARD), Clarke's Error Grid Method (Clarke EGA), and International Standard Organization (ISO) standards.

[0298] CGM systems also incorporate continuous glucose error grids (CG-EGA) to provide information about glucose variability: (1) point error grid analysis (P-EGA) to assess sensor accuracy with respect to accurate blood glucose measurement, and (2) rate error grid analysis (R-EGA) to assess the predictive ability of the sensor.

[0299] These in vivo sensor evaluation methods require true blood glucose concentrations to be determined using an external glucose measuring device (i.e., a fingerstick glucose sensor). A reliable and reproducible procedure for calibration during in vivo monitoring is critical to achieving accurate measurements.

[0300] CGM systems essentially estimate blood glucose concentrations by assuming that glucose concentrations in interstitial fluids are substantially similar, an assumption that is problematic because the blood / tissue glucose ratio is not constant but rather varies depending on metabolic rates associated with glucose and insulin physiology, including glucose uptake by cells and from the blood vessels, blood flow and capillary permeability.

[0301] The discrepancy in glucose concentration between blood and interstitial fluid is typically complex, varying based on time and concentration due to the patient's physical state, including resting state, hyperventilation, exercise, hypoxia, and hypoxia. The lag time between blood and subcutaneous tissue glucose concentrations further renders CGM devices inaccurate. Under normal conditions (i.e., conditions in which glucose levels do not change rapidly with activities such as exercise or eating), the lag time between blood and interstitial fluid glucose is 5-10 minutes. Longer and more unpredictable lag times are created by physiological differences between individuals, sensor-specific lag times (typically seconds to minutes) and noise filtering. Delays are also created by tissue responses to the sensor, such as electrode fouling, biofouling, and foreign body encapsulation that slows glucose diffusion to the sensor. Again, frequent calibration using an external glucose measurement device is required to ensure the accuracy of the CGM sensor.

[0302] "One-point" and "two-point" calibration procedures using blood glucose strips have been used to calibrate CGM sensors. The calibration process involves converting a time-dependent current signal (i(t)) into an estimate of the blood glucose concentration at a given time (CG(t)). Using the one-point calibration procedure, the sensor sensitivity (S) is determined as the ratio of the current signal to the blood glucose concentration from a single blood glucose measurement.

[0303] This approach is useful for highly sensitive sensors that have near-zero output current at zero glucose concentration. A two-point calibration procedure is preferred when the sensor output (i0) observed in the absence of glucose is not negligible. Two-point calibration involves the estimation of two parameters, S and i0, by determining the blood glucose concentration and the simultaneous sensor current at two different times. The glucose concentration is then estimated from the response current according to Equation 1:

[0304] A two-point calibration curve is CG(t)=(i(t)-i0) / S (1) which is not very accurate in practice due to errors associated with electrical noise and "true" fingerstick blood glucose measurements (allowed as ±10% error on commercial glucose meters) that result in significant positive or negative measurement artifacts. Therefore, a one-point calibration is considered more appropriate.

[0305] Even with accurate calibration, repeated calibrations are required because physiological variations and foreign body responses to the sensor cause changes in sensor sensitivity over time, however, by using the nitric oxide releasing polymers described herein, the number of required calibrations can be minimized because inaccuracies caused by foreign body responses are reduced.

[0306] In another embodiment, a subcutaneous continuous glucose monitor is disclosed that is modified to reduce foreign body responses when implanted.

[0307] Long-term electrochemical implantable (subcutaneous) glucose sensor In some embodiments, rather than using transdermal injection of a biosensor, the CGM is a subcutaneous implant, such as an implantable microdialysis probe or a long-term electrochemical implantable glucose sensor. While transcutaneous glucose sensors are typically used for less than a month (largely due to foreign body response), fully implanted (i.e., subcutaneous) glucose sensors can be used for significantly longer periods.

[0308] CGM devices with enzyme-immobilized amperometric biosensors are fully implanted subcutaneously and can be used for extended periods of time (months to years). Subcutaneous glucose sensors typically include a disk-shaped sensor with a titanium housing and measure oxygen consumption (FIG. 4B). In one embodiment, the device detects glucose concentration using fluorescence or chemiluminescence rather than GOx (glucose oxidation). One such device is the Eversense® device.

[0309] Fluorescent glucose biosensors typically measure glucose concentration by a sensitive protein that relays the concentration by fluorescence. Most of the fluorophores used in the sensors are small molecules, but some sensors are made using quantum dots (QDs) or fluorescent proteins.

[0310] Chemiluminescence is the production of light by a chemical reaction, which is produced by several proteins such as Aqueorin from the jellyfish symbiont and Luciferase from the firefly symbiont. These proteins are used to create glucose sensors. For example, Ggbp isolated aqueorin-based sensors and Ggbp luciferase with Asp459Asn (Glc instead of Gal)-based sensors have been developed.

[0311] In one embodiment, the subcutaneous sensor uses electrochemical fractional detection of oxygen via a two-step chemical reaction catalyzed by GOx and catalase. In some aspects of this embodiment, accurate glucose measurements can be performed for more than two years by taking into account the difference in oxygen reduction at an electrode that produces a glucose-modulated current and a reference electrode that produces an oxygen-dependent current.

[0312] The size of the sensor is typically larger than transdermal CGM systems (approximately 3 cm versus 3 microns) due to the power (i.e., battery) requirements to support longer use, which is minimized in some aspects of this embodiment by using alternative means to provide long-term power supply.

[0313] Such alternatives include those disclosed in Ben Amar et al., “Power Approaches for Implantable Medical Devices,” Sensors (Basel) 15(11):28889-28914 (2015).

[0314] In one aspect, energy is generated and harvested from potential sources around the implant, for example, using a biofuel cell that utilizes the abundant glucose and oxygen in the blood to generate energy (see, e.g., Wei and Liu, "Power sources and electrical recharging strategies for implantable medical devices," Front. Energy Power Eng. China, 2:1-13 (2008)).

[0315] In another aspect, body heat or motion, such as breathing and movement, can be used to power implanted medical devices (IMDs), replacing the need for traditional batteries. For example, thermoelectric generators can use the temperature difference between the inside and the skin (typically about 8°C) to generate hundreds of microwatts of electricity. Piezoelectric generators can use piezoelectric materials to convert kinetic energy into electricity. Electrostatic and electromagnetic mechanisms can be used to harvest energy from physical activity.

[0316] In yet another embodiment, energy is provided to the IMD using an external unit to either recharge the battery or provide continuous power to a "battery-less" implant. In various aspects of this embodiment, this can be accomplished optically, ultrasonically, and / or electromagnetically. Light charging methods include using a solar cell in the IMD that receives power from a light source that applies light, whether that be the use of an LED, OLED, or laser, typically operating in the near infrared or infrared range.

[0317] Inductive power transfer can also be used. This typically involves the use of a pair of antennas where power is transferred via a mutual inductive coupling link. Those skilled in the art can readily determine the appropriate antenna design and orientation, operating distance and frequency, and specified power for the implanted device.

[0318] A limitation of conventional subcutaneous sensors is that the sensor response changes over time due to collagen encapsulation, variations in local microvascular perfusion, and limited oxygen availability.

[0319] Because sensor implantation and subsequent replacement require surgery, followed in each case by a long stabilization period (approximately 2-3 weeks), it is desirable to minimize the number of times the device must be replaced and the number of times it must be recalibrated during operation.

[0320] To accomplish this, the implanted device can be coated with a coating described herein that provides a local concentration of nitric oxide around the implanted device. In some aspects of this embodiment, the coating comprises a polymer having pendant SNO groups, while in other aspects the coating comprises embedded particles that include compounds or particles having pendant SNO groups.

[0321] Method for measuring blood glucose level Methods for using the device to measure glucose levels while minimizing foreign body response to an implanted biosensor are also disclosed. In one embodiment, the method includes using a transcutaneous glucose monitor, and in another embodiment, the method includes using a subcutaneous glucose monitor.

[0322] Where the device is a transdermal glucose monitor, the approach described herein allows a user to wear a continuous glucose monitor for relatively long periods of time before it must be removed and replaced due to inaccuracies in glucose readings resulting from a foreign body response, as opposed to conventional transdermal (continuous) glucose monitors.

[0323] Methods of inhibiting a foreign body response to an implanted sensor, catheter, are also disclosed, which in some embodiments involve applying a transdermal continuous glucose monitor, insulin pump or other device, including an implanted sensor, catheter, port, shunt, etc., that is implanted into the skin of a user, where the device includes a coating that includes one or more compounds that produce nitric oxide.

[0324] In other embodiments, the embodiments involve implanting a subcutaneous continuous glucose monitor, insulin pump or other device including an implanted sensor, catheter, port that is injected into the user's skin, where the device includes a coating that includes one or more compounds that produce nitric oxide.

[0325] The methods described herein can be used to treat, prevent, manage, or reduce the severity of a foreign body response to an injected or implanted biosensor.

[0326] In some embodiments, the term "prevention" relates to preventing a foreign body response from occurring at all. In other embodiments, prevention relates to minimizing the foreign body response so that the biosensor does not lose the full sensitivity that would normally be seen as a result of a foreign body response over a period of about 21 days or up to 31 days. In the context of the use of continuous glucose monitors, there are reasons other than foreign body response that limit their useful lifespan. For example, continuous glucose monitors (CGMs) are glued to tissue, and the glue wears off over time. Regardless of whether the implanted biosensor still provides accurate readings, most users seek to replace it in about 30 days, for example due to loss of adhesion of the CGM to the skin.

[0327] The method includes applying a CGM to the skin, including adhering a body of the CGM to the skin while also infusing the skin with a biosensor, the CGM including a coating that provides local NO release to tissue surrounding the biosensor. NO can provide antibacterial effects, reduce inflammation, and increase angiogenesis.

[0328] Depending on the particular CGM, the device may need to be calibrated periodically, which is typically done by performing a finger prick and measuring blood glucose levels.

[0329] Preventing or minimizing foreign body responses means that the sensor will retain its accuracy over an extended period of time, allowing the user to calibrate the CGM relatively less frequently than if foreign body responses were not prevented or minimized.

[0330] Tissue Engineering Scaffolds In yet another embodiment, the medical device is a scaffold used in tissue engineering applications. Tissue engineering scaffolds act as an extracellular matrix that interacts with cells prior to the formation of new tissue. The chemical and structural properties of the scaffold are primarily related to the production of ideal three-dimensional structures for tissue engineering applications. Polymer scaffolds used in tissue engineering ideally have the appropriate structural and mechanical properties in addition to supporting cell adhesion, proliferation and differentiation. The scaffold is porous, and there is a trade-off between mechanical strength and porosity in that there must be sufficient porosity to allow cell infiltration, but not excessive porosity that compromises the mechanical strength of the scaffold.

[0331] The tissue scaffold typically includes cells that are intended to grow on the scaffold, such as stem cells, and other types of undifferentiated cells, which may include growth factors and other compounds that govern the proliferation and differentiation of the cells. In one aspect of this embodiment, the stem cells proliferate in approximately the same time frame as the scaffold degrades, thereby forming a three-dimensional tissue matrix of approximately the same shape as the scaffold.

[0332] Because tissue scaffolds are porous and typically degrade as cells embedded in the scaffold proliferate and / or differentiate, it is not desirable to cover the porous scaffold with a polymer that is not biodegradable and / or not porous.Thus, in one embodiment, the scaffold does not include a polymer coating that includes dyes, pigments and / or light-stabilizing compounds.Rather, the polymer used to prepare the scaffold and / or the particles or small molecules embedded within the polymer include dyes, pigments and / or light-stabilizing compounds to minimize the degradation of NO-releasing functional groups in the polymer, particles and / or small molecules when these functional groups are exposed to light.

[0333] Synthetic polymers poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(caprolactone) (PCL) and poly(lactic-co-glycolic) acid (PLGA) are commonly used to form three-dimensional structures in the form of scaffolds, either alone or in combination with natural polymers that can help improve hydrophilicity, cell attachment and biodegradability. These polymers can be prepared using thiolactic acid or another hydroxy acid with a thiol side chain to incorporate nitrosothiol groups into the final tissue scaffold when the thiol groups are converted to nitrosothiol groups. If the thiol groups may interfere with the polymerization chemistry or are converted to other functional groups and are not available for subsequent nitrosation to form nitrosothiol groups, the thiol groups can be protected during the polymerization process and subsequently deprotected. Protecting groups for thiols are well known to those skilled in the art.

[0334] In one aspect of this embodiment, the scaffold is formed from a polymer that includes pendant NO-releasing groups, such as diazeniumdiolates and / or nitrosothiol (SNO) groups. In another aspect of this embodiment, the scaffold is formed from a polymer that includes embedded particles, where the particles include one or more compounds. The polymer and / or embedded particles can be the same polymers and particles as described above for the NO-releasing coating.

[0335] Stitches / Surgical Staples In another embodiment, the device is an absorbable or non-absorbable stitch or surgical staple that can release nitric oxide at the wound site to inhibit infection and promote wound healing. Degradable or absorbable sutures can be degraded by the human body without the need for external removal and can be characterized by a loss of 50% or more of their tensile strength within 4 weeks after implantation. Degradable sutures can be made from both natural and synthetic polymers. Sterility is important both during the manufacture and use of these devices to minimize infection events as a result of introducing a foreign body into the body.

[0336] These devices can be used, for example, to close wounds or surgical incisions while releasing nitric oxide over time. This can aid in wound healing, increase vascularization, minimize scarring, and reduce the incidence of infection. In this embodiment, dyes, pigments, and / or light stabilizing compounds can be mixed into the polymer to provide light stability to the device, minimizing premature release of NO, as can occur during long-term storage in packaging that exposes the suture to light.

[0337] Degradable sutures are commonly prepared from PLA, PGA, PLGA and polydioxanone (PDS), a synthetic homopolymer, prepared by polymerization of the monomer paradioxanone, having the following formula: [ka]

[0338] These types of sutures are often prepared by melt extrusion of the polymeric material into a monofilament form. The melt extrusion process degrades certain NO-releasing functional groups, but in embodiments where the NO-releasing functional groups are significantly degraded during the melt extrusion process, the NO-functional groups can be formed after the suture is prepared.

[0339] As with other degradable materials formed from PLA, PGA, PLGA, thiol-containing monomers such as thiolactic acid, cysteine, etc. can be blended with the monomers used to prepare the degradable materials to provide biodegradable polymeric materials with pendant thiol groups that, in some embodiments, can be converted to NO-releasing nitrosothiol groups after the sutures are fabricated.

[0340] In some embodiments, the degradable polymer itself does not contain NO-releasing functional groups, but contains embedded small molecules or particles that do contain NO-releasing functional groups.

[0341] Monolith / Film / Tape In yet other embodiments, "monoliths" or tapes or films incorporating NO releasing groups on small molecules and / or polymers can be physically or chemically attached to medical devices such as implants. In some aspects of these embodiments, the implant / monolith or implant / tape compounds are coated with a layer comprising a dye, pigment or light stabilizing complex, while in other aspects the monolith or tape further comprises a dye, pigment or light stabilizing compound.

[0342] In some aspects of this embodiment, the tape / film coats all or a portion of a medical device selected from the group consisting of arterial stents, guidewires, catheters, trocars, needles, bone anchors, bone screws, protection plates, hip or joint replacements, electrical leads, biosensors, probes, sutures, surgical drapes, wound dressings and bandages.

[0343] The tape or film can be physically or chemically attached to the medical device, such as an implant. If the tape or film is chemically attached, it preferably comprises a biocompatible adhesive, preferably a biodegradable adhesive. Such adhesives are well known to those skilled in the art. One-part and two-part epoxy and silicone biocompatible adhesives can be used, which can be a variety of light-cured materials, epoxy-polyurethane blends and cyanoacrylates. In one embodiment, the adhesive is a biocompatible and biodegradable polyurethane adhesive. In another embodiment, the adhesive is poly(glycerol sebacate acrylate) (PGSA).

[0344] Surgical / tissue adhesives An ideal tissue adhesive, particularly for pulmonary, cardiovascular and / or gastrointestinal applications, would ideally have the following properties: (1) low viscosity or liquid-like properties before curing, allowing for easy application to the desired area; (2) minimal flushing and activation by bodily fluids only as desired to facilitate delivery and repositioning of implanted devices during minimally invasive procedures; (3) exceptional adhesive strength, especially in the presence of blood and / or other body fluids; (4) the ability to withstand mechanical loads due to attachment to highly mobile tissues (e.g., contraction of the heart or pulsation in large blood vessels); (5) the ability to form a hemostatic seal; (6) minimal inflammatory response, and (7) Biodegradable, in whole or in large part.

[0345] In addition to these properties, it may be advantageous for the surgical adhesive to release nitric oxide over time, as it can minimize microbial contamination often associated with surgery, promote wound healing, increase vascularization around implants, and minimize scar formation.The surgical / tissue adhesives described herein provide such nitric oxide release.

[0346] Many surgical adhesives in use today contain one or more of (meth)acrylate functional groups, or cyanoacrylates, or combinations of albumin and glutaraldehyde, or contain poly(ethylene glycol) (PEG) blocks, or contain polyurethanes, or are composed of fibrin.

[0347] Cyanoacrylates belong to a class of monomers consisting of alkyl esters of 2-cyanoacrylic acid. To date, methyl cyanoacrylate, ethyl cyanoacrylate, n-butyl cyanoacrylate, isohexyl cyanoacrylate, and octyl cyanoacrylate have been used. Butyl-2-cyanoacrylate adhesives include Indermil® (Covidien), Histoacryl® and Histoacryl® Blue (TissueSeal), and LiquiBand® (Advanced Medical Solutions).

[0348] Octyl-2-cyanoacrylate adhesives include Dermabond® (Ethicon), SurgiSeal™ (Adhezion Biomedical), LiquiBand® Flex (Advanced Medical Solutions), and OctylSeal Medline Industries).

[0349] Cyanoacrylates provide tensile strength similar to that of absorbable sutures for closing skin wounds and can adhere to most tissue surfaces, but are not suggested for use in high tension areas, across joints, mucosal surfaces, mucocutaneous junctions or areas of dense hair growth.

[0350] Artiss (Baxter) is a fibrin product approved for attachment of skin grafts to wounded skin caused by burns and tissue flaps during facial wrinkle reduction surgery. This fibrin product is formed from pooled human plasma.

[0351] While medical grade cyanoacrylates (CA) or fibrin sealants are often used, they may not have all or even most of the desired properties for a surgical adhesive, however, nitric oxide releasing particles or small molecules can be blended with these surgical adhesives and at least they may have the beneficial properties associated with nitric oxide release.

[0352] BioGlue® (CryoLife) is a surgical adhesive approved for use in vascular sealing of large blood vessels in conjunction with sutures for hemostasis, and to assist in the repair of aortic dissections to provide stronger vessel walls after vascular surgery. BioGlue is a mixture of purified bovine serum albumin (BSA) and glutaraldehyde that polymerizes in situ at the application site within 30 seconds and achieves full strength within 2 minutes.

[0353] TissuGlu® (Cohera Medical Inc) is used for abdominal tissue bonding to help reduce fluid accumulation under the skin. TissuGlu® is applied to the lower abdominal layer to approximate the muscle layer to the skin flap and help prevent seroma, a pocket of clear serous fluid under the skin after abdominoplasty (tummy tuck). The product contains a hyperbranched polyurethane with isocyanate end groups and lysine. The amine groups in the lysine crosslink with the isocyanate groups, resulting in adhesive crosslinking within 25 minutes.

[0354] PEG-based sealants include FocalSeal® (Genzyme Biosurgery), Progel™ (Neomend), Duraseal™ and Duraseal™ Xact (Covidien), Coseal® (Baxter), and ReSure Sealant (Ocular Therapeutix, Inc.) are commercially available PEG-based sealants currently approved by the FDA for clinical use. Although all are classified as PEG-based, differences exist in the polymers used and their indicated uses.

[0355] Focalseal® (Genzyme Biosurgery, Inc. Cambridge, MA) is a polyethylene glycol-based synthetic hydrogel that is a block copolymer containing one or more polyethylene glycol blocks and one or more PLGA blocks, which also contains carbonate linkages and contains (meth)acrylate end caps. The adhesive minimizes tissue adhesion due to the polyethylene glycol blocks (thereby minimizing scarring) and is degradable due to the PLGA blocks. It is also adhered to the skin using the (meth)acrylate end groups, and can be reacted with functional groups on the tissue surface by applying light and an amine (which generates free radicals used to cure the (meth)acrylate groups) to the skin surface.

[0356] Focalseal® is a PEG-co-trimethylene carbonate-co-lactide with acrylated end groups, and Eosin Y is added as an ingredient to generate free radicals that react with light after the adhesive is applied to polymerize the polymer in situ. Focalseal® is FDA approved as a sealant to limit air leaks after lung resections, and is also used as a hemostatic adjunct to prevent anastomotic bleeding and to seal other types of closures such as dura, pancreatic stumps, and open wounds. The sealant has two components, a primer and a sealant, and is applied in two steps, after which the (meth)acrylate end cap groups on the polymer are polymerized using visible light, typically blue-green light. The sealant degrades by hydrolysis of the biodegradable blocks. The sealant is flexible in part through carbonate bonds, and is non-toxic.

[0357] ProGel™ contains human serum albumin (HSA) and di-PEG-succinimidyl succinate, which crosslink together and are applied using a dual syringe to avoid mixing of the components prior to application, allowing them to harden in place by crosslinking upon application.

[0358] DuraSeal™ contains tetra-PEG-succinimidyl ester and trilysine amine, formulations that are applied using a dual syringe and can crosslink upon application. DuraSeal™ is used as an adjunct to sutured dural repair during cranial surgery, providing a watertight closure.

[0359] Coseal®, which contains tetra-PEG-succinimidyl ester and is tetra-thiol derivatized, is used to manage anastomotic bleeding during aortic reconstruction after graft implantation and to stop bleeding from anastomotic suture holes.

[0360] Improvements to these types of adhesives are disclosed herein. In one embodiment, the surgical adhesive is a block copolymer that includes one or more polyalkylene glycol blocks, such as polyethylene glycol blocks, and one or more degradable blocks.

[0361] In some embodiments, the degradable blocks are formed from any suitable combination of degradable monomeric units, such as lactic acid, glycolic acid, hydroxybutyric acid, caprolactone, carbonate, and the like, and in some embodiments, they are peptides such as trilysine or other short chain (i.e., less than 25 monomeric units) peptides containing three or more lysine monomeric units, or proteins such as albumin.

[0362] In some embodiments, the surgical adhesive also includes vinyl groups (such as (meth)acrylate groups) that can be polymerized via free radical polymerization. In other embodiments, the surgical adhesive is a two or more component system, where one component includes functional groups that can crosslink with functional groups on another component.

[0363] In one embodiment, a block of polyalkylene glycol, such as polyethylene glycol, contains functional groups that crosslink with different functional groups on the degradable block, and one of skill in the art will understand which functional groups are capable of crosslinking with other functional groups under physiological conditions.

[0364] In one aspect of this embodiment, the degradable block comprises one or more monomer units containing pendant thiol or amine groups, which can be modified to form nitrosothiols, diazeniumdiolates, or other NO-releasing groups before the adhesive is applied. In this embodiment, it is important that the nitrosothiols, diazeniumdiolates, or other NO-releasing functional groups do not interfere with the crosslinking chemistry. In another embodiment, the surgical adhesive is blended with particles or small molecules containing NO-releasing functional groups. A combination of these approaches can be used.

[0365] Other surgical adhesives that are cured by free radical polymerization of vinyl groups such as (meth)acrylate groups include those disclosed in U.S. Patent No. 8,143,042 to Bettinger et al. The '042 patent discloses biodegradable elastomers prepared by crosslinking prepolymers that contain crosslinkable functional groups such as acrylate groups. In some embodiments, the prepolymers can have a molecular weight of about 300 Daltons to 75,000 Daltons and have various degrees of (meth)acrylation.

[0366] The primary adhesion mechanism of the polymers disclosed in the '042 patent, and many other surgical adhesives known in the art, is a chemical interaction between functional groups (e.g., free hydroxy groups) on the polymer and the tissue to which it is applied. In this way, in some embodiments, it is not necessary for the surgical adhesive to contain two or more components that crosslink with each other, so long as the surgical adhesive contains one or more functional groups that crosslink with groups found on the tissue surface to which it is adhered.

[0367] The elastomers can be modified to include monomeric units with pendant thiol or amine groups and converted to nitrosothiol, diazeniumdiolate, or other NO-releasing groups, resulting in NO release after the adhesive is applied and the surgical adhesive is exposed to physiological fluids. Alternatively, the surgical adhesive can be blended with particles or small molecules that contain NO-releasing functional groups.

[0368] Similarly, Mandavi et al. in PNAS (2008, 2307-2312) describes nanopatterning elastomeric PGSA polymers with a thin layer of aldehyde-functionalized oxidized dextran (DXTA) to increase the adhesive strength of the adhesive by promoting covalent crosslinking of the terminal aldehyde groups of DXTA with amine groups in tissue proteins. This adhesion mechanism is essentially based on covalent bonding between radicals generated during the curing process and functional groups on the tissue surface. This type of reactive chemistry potentially promotes undesirable immune responses such as local inflammation, but the immune response can be minimized by the local release of nitric oxide, resulting in a more stable surgical adhesion.

[0369] US Patent No. 9,724,447 also discloses surgical adhesives, but these adhesives include prepolymers that can be applied by syringe or catheter and have flow properties that are viscous enough to stay in place at the application site but do not flow out of the tissue. The prepolymers are also hydrophobic enough to resist washing away by bodily fluids and are stable in bodily fluids. That is, the prepolymers do not spontaneously crosslink in bodily fluids without the presence of a stimulus purposefully applied to initiate crosslinking. Upon crosslinking, the adhesives exhibit significant adhesive strength in the presence of blood and other bodily fluids. The adhesives are elastic enough to be able to resist movement of the underlying tissue and can be a biodegradable and biocompatible seal for hemostasis.

[0370] The prepolymer has the formula (-AB) n where A is derived from a substituted or unsubstituted polyol moiety, B is derived from a substituted or unsubstituted diacid, and n represents an integer equal to or greater than 1. The prepolymer comprises a plurality of polymer backbones activated with functional groups, including substituted or unsubstituted vinyl groups, such as (meth)acrylate groups, that are crosslinkable upon exposure to light, heat, or a chemical (free radical) initiator. The prepolymer has a weight average molecular weight of about 1,000 to less than 20,000 Daltons.

[0371] In one embodiment not disclosed in the '447 patent, at least a portion of the diacid and / or diol monomers used to prepare the surgical adhesive contain pendant thiol or amine groups, or other NO-releasing groups, that are converted to nitrosothiol or diazeniumdiolate groups before the adhesive is applied. In another embodiment, the surgical adhesive is blended with a particle or small molecule that contains an NO-releasing functional group. In any of these embodiments, it may be preferred to cure using a free radical initiator rather than light or heat, since light and heat may at least partially decompose the NO-releasing group, reducing the NO payload of the surgical adhesive.

[0372] Subdermal implant In another embodiment, the medical device is a subdermal implant comprising a coating comprising a biocompatible polymer, optionally a biodegradable polymer, and optionally comprising embedded particles. Exemplary subdermal implants include artificial joints, pacemakers, subcutaneous glucose monitors, stents, insulin infusion sets, shunts such as hydrocephilic shunts, reconstructive cosmetic implants including breast implants, calf implants, and buttock implants. With respect to stents, nitric oxide release from a coating on the stent can minimize restenosis.

[0373] Medical Implants A medical implant is a medical device manufactured to replace missing biological structures, support damaged biological structures, or reinforce existing biological structures. Medical implants are artificial devices, as opposed to grafts that are implanted into biomedical tissue. The surface of the implant that contacts the body can be made from biomedical materials such as titanium, silicone, apatite, and / or plastics such as high density polyethylene (HDPE) or ultra-high density polyethylene (UHDPE), depending on the device.

[0374] In some cases, implants such as artificial pacemakers, implantable cardioverter defibrillators, and cochlear implants contain electronic devices. Some implants, such as subcutaneous drug delivery devices, are bioactive. Representative subcutaneous drug delivery devices include implantable pills and drug-eluting stents. Orthopedic implants can be used to repair fractures or replace missing bone and / or cartilage. Certain implants support the function of an organ or organ system. Examples include coronary vascular implants, gastrointestinal implants, respiratory implants, and urinary implants. Sensory and neural implants can also be treated using the tapes and monoliths described herein. Coronary vascular stents, such as drug-eluting stents, are another common article implanted in humans. Orthopedic implants are used to repair fractures, such as fractures of the radius and ulna.

[0375] Further details regarding the various types of implants are provided below.

[0376] Sensory and Neural Implants Sensory and neural implants are used for disorders affecting the primary senses and the brain, as well as other neurological disorders. They are predominantly used to treat conditions such as cataracts, glaucoma, keratoconus and other visual impairments, otosclerosis and other hearing problems, and middle ear diseases such as otitis media, as well as neurological disorders such as epilepsy, Parkinson's disease, and treatment-resistant depression. Examples include intraocular lenses, intrastromal corneal segments, cochlear implants, tympanostomy tubes, and neurostimulators.

[0377] Cardiovascular Implants Cardiovascular medical devices are implanted when the heart, its valves, and the rest of the circulatory system are in a compromised state. They are used to treat conditions such as heart failure, arrhythmias, ventricular tachycardia, valvular heart disease, angina pectoris, and atherosclerosis. Examples include artificial hearts, artificial heart valves, implantable cardioverter defibrillators, cardiac pacemakers, and coronary stents.

[0378] Orthopedic Implants Orthopedic implants help alleviate problems with the bones and joints of the body. They are used to treat bone fractures, osteoarthritis, scoliosis, spinal stenosis, and chronic pain. Examples include the wide range of pins, rods, screws, and plates that are used to stabilize broken bones while they heal.

[0379] Representative orthopedic implants include the Austin-Moore prosthesis for femoral neck fractures, the Baksi prosthesis for elbow replacement, the Charnley prosthesis for total hip replacement, the Condylar blade plate for femoral condyle fractures, the Ender nail for fixation of trochanteric fractures, the Grosse-Kempf nail for tibial or femoral shaft fractures, the Hansson pin (or LIH for Lars Ingvar Hansson), the hook pin used for femoral neck fractures, the Harrington rod for spinal fixation, the Hartshill rectangle for spinal fixation, and the Insall for total knee replacement. These include the Burstein prosthesis, the Wohns interspinous implant and implant device intended to be implanted between two adjacent vertebrae, the Kirschner wire for fixation of small bones, the Kuntscher nail for fractures of the shaft of the femur, the Luque rod for fixation of the spine, the Moore pin for fractures of the femoral neck, the Neer prosthesis for shoulder replacement, the Rush nail for fractures of the shaft of long bones, the Smith Peterson nail for fractures of the femoral neck, the Smith Peterson nail with McLaughlin plate for fractures of the trochanter, the Seidel nail for fractures of the humeral shaft, the Souter prosthesis for elbow replacement, the Steffee plate for spinal fixation, the Steinmann pin for skeletal traction, the Swanson prosthesis for finger joint replacement, the Talwalkar nail for fractures of the radius and ulna, and the Thompson prosthesis for fractures of the femoral neck.

[0380] Electrical implants Electrical implants can be used, for example, to reduce pain and suffering from rheumatoid arthritis, or chronic back or neck pain, in one embodiment, an electrical implant is implanted in the neck of a patient with rheumatoid arthritis, and the implant sends an electrical signal to an electrode in the vagus nerve.

[0381] Neurostimulation has been approved as a treatment for chronic lower back pain (CLBP), and implants such as ReActiv8 (Mainstay Medical) can be used to treat CLBP. These types of implants work by sending electrical signals that stimulate dormant nerve tissue within the multifidus muscle.

[0382] The deep multifidus muscle (specifically the lumbar portion) is one of the most important stabilizers of the lumbar spine, important for walking, sitting, and especially bending. When this muscle atrophies from lack of use or breaks down from overuse / injury, people commonly experience impaired motor control of the lower back. Implants can be used to treat multifidus dysfunction by using electrical stimulation of the nerves (neurostimulation) to induce contractions in the lumbar muscles, correcting the muscle weakness that causes lower back pain.

[0383] The deep multifidus (specifically the lumbar portion) is one of the most important stabilizers of the lumbar spine, important for walking, sitting and especially flexion. When this muscle atrophies from lack of use or breaks down due to overuse / injury, people commonly experience impaired motor control of the lower back.

[0384] This impaired control is one of the major underlying causes of CLBP. Thus, an implant intended to treat CLBP can function by restoring the contractile ability of the multifidus muscle, thereby allowing lumbar control again. The implanted pulse generator can provide electrical stimulation to the posterior branch nerve, the nerve that passes through the multifidus muscle. This stimulation induces repetitive contractions of the multifidus muscle, thereby addressing the cause of CLBP.

[0385] Contraceptive implants Contraceptive implants are primarily used to prevent unintended pregnancy and to treat conditions such as non-pathological forms of menorrhagia. Examples include copper and hormone-based intrauterine devices.

[0386] Contraceptive implants are a type of hormonal contraception that typically deliver progestin hormones to the body to prevent pregnancy. In one embodiment, the implant is a very small plastic rod, about the size of a matchstick, that is inserted under the skin into the upper arm. Intrauterine devices are another type of contraceptive implant.

[0387] Nitric oxide reduces sperm motility by inhibiting cellular respiration, possibly independent of the elevation of intracellular cGMP. Nitric oxide produced in vivo in the female or male reproductive tract can adversely affect sperm function and fertility. Weinberg JB, Doty E, Bonaventura J, Haney AF, "Nitric oxide inhibition of human sperm motility", Fertil Steril. 1995 Aug;64(2):408-13 (1995). Thus, nitric oxide releasing diaphragms can further reduce fertility by not only physically blocking sperm from reaching the egg, but also by inhibiting sperm motility. Conventional diaphragms can be modified by adhering a tape or monolith or by spraying one or more sides of the diaphragm with a sprayable formulation.

[0388] Cosmetic implants Cosmetic implants, including prostheses, attempt to bring some part of the body back to an acceptable aesthetic standard. They are used as a follow-up to mastectomy for breast cancer, to correct some disfiguring features (as with buttock augmentation and chin augmentation), and to modify an aspect of the body. Examples include breast, calf, chin and buttock implants, nasal prostheses, eye prostheses and testicular prostheses.

[0389] Cardiac implants Cardiac implants include pacemakers, implantable cardioverter defibrillators and stents, including drug-loaded stents.

[0390] A cardiac pacemaker generates electrical impulses delivered by electrodes to the myocardial chambers (upper or atrium and / or lower or ventricle) to contract and thereby pump blood. The pacemaker replaces and / or regulates the function of the heart's electrical conduction system by maintaining an appropriate heart rate. In some embodiments, the pacemaker is externally programmable, allowing the cardiologist to select the optimal pacing mode for an individual patient. In some embodiments, the pacemaker is a demand-type pacemaker, in which stimulation of the heart is based on the dynamic demands of the circulatory system. One type of pacemaker is a defibrillator, which combines pacemaker and defibrillator functions in a single implantable device. Another type is a biventricular pacemaker, which includes multiple electrodes that stimulate different locations within the lower chamber of the heart, the ventricles, to improve synchronization of the lower chambers of the heart.

[0391] An implantable cardioverter-defibrillator (ICD) or automated implantable cardioverter defibrillator (AICD) is a device that can be implanted in the body that is capable of cardioversion, defibrillation, and (in the latest versions) pacing the heart. The device is thus capable of correcting the most life-threatening arrhythmias. ICDs are the first-line treatment and preventative therapy for patients at risk of sudden cardiac death due to ventricular fibrillation and ventricular tachycardia. Current devices can be programmed to detect abnormal heart rhythms and deliver therapy via programmable anti-tachycardia pacing, in addition to low-energy and high-energy shocks.

[0392] Implants that stimulate other organs and organ systems Other types of organ dysfunction can occur in other body systems, including the gastrointestinal, respiratory and urinary systems. Implants are used in these and other locations to treat conditions such as gastroesophageal reflux disease, gastroparesis, respiratory failure, sleep apnea, urinary and fecal incontinence, and erectile dysfunction.

[0393] Examples include insulin pumps, LINX, implantable gastric stimulators, diaphragm / phrenic nerve stimulators, neurostimulators, surgical mesh, artificial urinary sphincters and penile implants.

[0394] Porous implants In some embodiments, the implant is porous. Porosity in the implant serves two main purposes: the elastic modulus of the implant is reduced, allowing the implant to better match other elastic moduli. The elastic modulus of cortical bone (about 18 MPa) is significantly lower than that of a typical solid titanium or steel implant (110 MPa and 210 MPa, respectively), allowing the implant to absorb a significant amount of the load applied to the appendage, resulting in an effect called stress shielding. This undesirable effect can be minimized by using a porous implant.

[0395] Porosity also allows osteoblasts to grow into the pores of the implant. Cells can span gaps smaller than 75 microns and extend into pores larger than 200 microns. Bone anchorage is a positive effect since it anchors the cells inside the implant and increases the strength of the bone-implant interface. More load is transferred from the implant to the bone, reducing the stress shielding effect. Bone density around the implant can be higher due to the increased load applied to the bone. Bone anchorage reduces the likelihood of the implant loosening over time since stress shielding and corresponding bone resorption are minimized. In embodiments where it is desired to infiltrate osteoblasts into the implant, it is desirable for the implant, or at least the surface of the implant, to have a porosity of greater than 40% to promote adequate anchoring of osteoblasts.

[0396] In some embodiments, to avoid problems associated with foreign body responses, all or a portion of the pores can be filled with a degradable material that releases NO over time, which helps to minimize the foreign body response. As the material degrades, osteoblasts can fill the pores, which may optionally contain fibroblast growth factors, as these can help to control osteoblast differentiation, particularly by seeding the material used to fill the pores with osteoblasts (PJ Marie, "Fibroblast growth factor signaling controlling osteoblast differentiation", Gene, Volume 316, pp. 23-32 (2003)).

[0397] Percutaneous implant In some embodiments, the medical device is a percutaneous implant. Exemplary percutaneous implants include transcutaneous glucose monitors, catheters / ports including urinary catheters and chemotherapy venous ports / catheters (e.g., indwelling ports), as well as open ports, fluid evacuation devices (drains), drug delivery devices, blood sampling devices, and percutaneously implanted neurostimulator electrode arrays.

[0398] Catheters, fluid drainage devices (i.e., drains), drug delivery devices, and blood collection devices can be modified by adhering a tape or monolith or spraying with a sprayable formulation described herein, which upon implantation releases nitric oxide onto the tape, monolith, or formulation. The release of nitric oxide can inhibit bacterial growth in and around the device and inhibit foreign body responses to the device. As an example, urinary catheters can cause urinary infections, and the release of nitric oxide from the catheter can minimize the chance of infection.

[0399] Fluid drainage devices (e.g., drains) can be used to drain, for example, ascites, or fluid that accumulates around the patient's heart, or fluid that accumulates around a surgical site, and the release of nitric oxide minimizes microbial contamination and promotes wound healing.

[0400] Drug delivery and blood collection devices typically include tubes that are inserted into a patient for the purpose of delivering drugs over an extended period of time or for repeated blood collection. Examples include ports, such as chest ports. The tissue surrounding these ports can be subject to infection and / or foreign body response, which can be minimized using the tapes, monoliths, or sprayable formulations described herein.

[0401] Treatment method Also disclosed are methods of treatment using the devices described herein. The medical devices prepared according to the methods described herein are used to deliver NO to a treatment site in an individual or animal. A "treatment site" includes a site in the body of an individual or animal where a desired therapeutic effect can be achieved by contacting the site with NO. An "individual" refers to animals, including humans and veterinary animals such as dogs and cats, and livestock animals such as horses, cows, and pigs.

[0402] Treatment sites include sites within the body that develop a foreign body response to an implanted medical device, for example, where the medical device is a continuous glucose monitor, the foreign body response may foul the glucose sensor, necessitating replacement of the continuous glucose monitor.

[0403] In the case where the medical device is a stent, restenosis, injury or thrombosis may result from trauma caused by contacting the site with a synthetic material or medical device. For example, restenosis may develop in blood vessels undergoing coronary or peripheral procedures (e.g., percutaneous transluminal angioplasty) using PTCA balloon catheters. Restenosis is the development of scar tissue approximately 3-6 months after the procedure, resulting in narrowing of the blood vessel. NO reduces restenosis by inhibiting platelet deposition and smooth muscle proliferation. NO can also inhibit thrombosis by inhibiting platelets and limit injury by acting as an anti-inflammatory agent.

[0404] Treatment sites may also occur at non-vascular sites, such as sites where a beneficial therapeutic effect can be achieved by reducing inflammatory responses. Examples include the airways, digestive tract, bladder, uterus, and corpus cavernosum. In this way, the compositions, methods, and devices described herein can be used to treat respiratory disorders, gastrointestinal disorders, urinary disorders, impotence, uterine dysfunction, and premature birth. Delivery of NO at treatment sites can also result in smooth muscle relaxation, facilitating the insertion of medical devices in procedures such as bronchoscopy, endoscopy, laparoscopy, and cystoscopy. Delivery of NO can also be used to prevent cerebral vasospasm after hemorrhage, and to treat neurogenic cystitis, urethral stricture, and cholespasm.

[0405] The method of delivering NO to a treatment site of an individual or animal includes implanting a medical device coated with a polymer sprayed with the composition or a medical device to which a tape or monolith is applied as described herein at the treatment site. NO can be delivered to a body fluid, such as blood, by contacting the body fluid with a medical device coated with the polymer of the present invention. A preferred polymer is an S-nitrosylated polymer as defined above. The treatment site of an individual or animal, a medical device suitable for implantation at the treatment site, and a medical device suitable for contacting a body fluid such as blood are described in the above paragraphs.

[0406] "Implantation of a medical device at a treatment site" refers to actually physically contacting the medical device with the treatment site, or alternatively, bringing the medical device close enough to the treatment site so that NO released from the medical device is in physical contact with the treatment site. For example, when bodily fluids are temporarily removed from the body for treatment with a medical device, the bodily fluids come into contact with the medical device coated with the polymer of the present invention, and the polymer coating is the interface between the bodily fluids and the medical device. Examples include the removal of blood for dialysis or by a heart-lung machine.

[0407] Also disclosed is a method for monitoring glucose levels using a transdermal glucose monitor with a sensor coated with an NO-releasing coating. In some embodiments, the coating further comprises a dye, pigment and / or a photo-stabilizing compound that minimizes premature degradation of the NO-releasing compound in the coating, or a second coating comprising a dye, pigment and / or a photo-stabilizing compound covers the coating. This also applies to the sprays, tapes and monoliths described herein.

[0408] Methods for minimizing foreign body responses with implanted medical devices - Patents.com Also disclosed are methods of minimizing foreign body response to implanted medical devices, such as transdermal or subcutaneous implants, by coating the NO-releasing medical devices described herein, spraying a NO-releasing composition onto the device, applying a NO-releasing tape to the device, and / or applying a NO-releasing monolith to the device. All medical devices contain polymers, particles, or small molecules that contain NO-releasing functional groups that release nitric oxide when exposed to physiological fluids. In some embodiments, the coating, spray, tape, and / or monolith also contain pigments, dyes, or light-stabilizing compounds that minimize the degradation of the NO-releasing functional groups when exposed to light.

[0409] Implantation of these devices may therefore release nitric oxide and reduce the foreign body response to the implanted device compared to devices that do not include a coating that includes or is formed from a material that releases nitric oxide over time.

[0410] The methods described herein can be used to treat, prevent, manage or reduce the severity of a foreign body response to an injected or implanted medical device. In some embodiments, the term "prevent" relates to preventing a foreign body response from occurring at all.

[0411] The invention will be better understood with reference to the following non-limiting examples. EXAMPLES

[0412] Example 1: Medical Device Containing NO-Releasing and Light-Blocking Particles 1 shows a representative medical device (104), such as a stent, port, sensor, etc., in contact with human tissue (110) at an interface (108). The medical device (104) includes a NO-releasing coating, tape, or monolith (102), which includes NO-releasing biodegradable particles (106).

[0413] Figure 2 is similar to Figure 1, except that it illustrates a condition in which some of the particles (106) have diffused out of the coating and are left behind inside the host tissue. In this state, the particles may continue to release any remaining NO payload or may simply continue to degrade via normal metabolic pathways.

[0414] Example 2: Surgical Adhesives / Sealants Figure 3 is a diagram of a surgical adhesive (116) containing NO-releasing biodegradable particles (106). The adhesive is shown disposed within a wound site (114) of host tissue (110). The adhesive is applied across the skin surface (112) where the wound separates the skin, and is applied to the full depth of the wound. The release of nitric oxide helps promote wound healing and reduce scar formation. Thus, the surgical adhesives described herein accelerate the healing process.

[0415] Example 3: Tissue scaffolds 4 is a diagram of a tissue scaffold (118) containing NO-releasing biodegradable particles (106) on a substrate (110), such as human tissue when implanted or a petri dish, plate, etc. when not implanted. The scaffold can be prepared from similar materials as the particles or from significantly different materials, depending on the requirements of each particular application. NO promotes tissue growth and vascularization and reduces scar tissue formation.

[0416] Example 4: NO-releasing transdermal glucose sensor particle manufacturing A polycaprolactone solution was prepared and used to fabricate biodegradable particles. An aqueous hydrophilic polyurethane dispersion was used as the base coating solution. Polycaprolactone (PC) (4.50 g, ALDRICH catalog number 440744) was placed in a glass vial (250 mL) that also contained tetrahydrofuran (180.0 mL, ALDRICH catalog number 401757-1L). The vial was sonicated in a heating bath (approximately 40 °C) until the polymer was completely dissolved (4-6 hours). To this solution, thiolactic acid (TLA) (0.50 g, ALDRICH catalog number T31003-100G) was added to create a mixture with a total solids of approximately 3 wt%. The solution was homogenized (30 seconds) using a laboratory vortex mixer. The solution was then loaded into a Buchi nano spray dryer B-90HP, which was used to prepare 200 nm dry particles. The resulting biodegradable particles consisted of approximately 10% TLA by weight.

[0417] Particle nitrosation TLA-loaded PC particles (100 mg) were placed in a glass scintillation vial (20 mL). The particles were suspended in MeOH (5.0 mL) at -20°C. HCl solution (5 M, 2.0 mL) was then added to the vial. In a second vial (20 mL), NaNO2 (0.100 g) was dissolved in EDTA solution (500 μM, 2.0 mL). This solution was then combined with the first vial and the reaction was allowed to proceed for 2 hours at 0°C in the dark. The crude reaction mixture was placed in a foil-covered conical tube (50 mL) with -20°C methanol (30 mL). The tube was mixed and allowed to sit for 2 minutes. It was then placed in a centrifuge (4500 rpm, 10 minutes, 4°C) to force the particles to the bottom of the tube, after which the supernatant was discarded. To wash the particles in this manner, they were resuspended in cold methanol three times. After the final wash, the particles were dried in a vacuum chamber (-30 inHg for 1 hour). Thus, the TLA-embedded PC particles were loaded with NO.

[0418] CGM Coating NO-loaded PC particles (100 mg) were placed in a scintillation vial (20 mL). To this vial, aqueous polyurethane dispersion (1.2 mL, Baymedix CD104, COVESTRO, Pittsburg, PA) was added and suspended in the dispersion using a laboratory vortex mixer (10 s). CGM sensors were coated using a Chemat DipMaster 50 Dip Coater (Northridge, CA). The sensors were immersed in the solution (3 coats, 5 min drying time between coats) to obtain a final coating thickness of 20-40 μm.

[0419] Those skilled in the art will recognize medical devices (existing or developed in the future) that may not yet be known to them, as well as medical devices that can deliver nitric oxide to tissues surrounding an implanted medical device, such as, for example, biosensors other than those that operate via a glucose oxidase mechanism, and injected biosensors, including devices that are applied to tissue rather than implanted. All such devices are within the scope of devices that can be used to practice the methods described herein.

[0420] Example 5 Medical Device Comprising a Tape Containing NO-Releasing Particles Polymer synthesis A polycaprolactone solution was prepared and used to fabricate biodegradable particles. An aqueous hydrophilic polyurethane dispersion was used as the base coating solution. Polycaprolactone (PC) (4.50 g, ALDRICH catalog number 440744) was placed in a glass vial (250 mL) that also contained tetrahydrofuran (180.0 mL, ALDRICH catalog number 401757-1L). The vial was sonicated in a heating bath (approximately 40 °C) until the polymer was completely dissolved (4-6 hours). To this solution, thiolactic acid (TLA) (0.50 g, ALDRICH catalog number T31003-100G) was added to create a mixture with a total solids of approximately 3 wt%. The solution was homogenized (30 seconds) using a laboratory vortex mixer. The solution was then loaded into a Buchi nano spray dryer B-90HP, which was used to prepare 200 nm dry particles. The resulting biodegradable particles consisted of approximately 10% TLA by weight.

[0421] Particle nitrosation TLA-loaded PC particles (100 mg) were placed in a glass scintillation vial (20 mL). The particles were suspended in MeOH (5.0 mL) at -20°C. HCl solution (5 M, 2.0 mL) was then added to the vial. In a second vial (20 mL), NaNO2 (0.100 g) was dissolved in EDTA solution (500 μM, 2.0 mL). This solution was then combined with the first vial and the reaction was allowed to proceed for 2 hours at 0°C in the dark. The crude reaction mixture was placed in a foil-covered conical tube (50 mL) with -20°C methanol (30 mL). The tube was mixed and allowed to sit for 2 minutes. It was then placed in a centrifuge (4500 rpm, 10 minutes, 4°C) to force the particles to the bottom of the tube, after which the supernatant was discarded. To wash the particles in this manner, they were resuspended in cold methanol three times. After the final wash, the particles were dried in a vacuum chamber (-30 inHg for 1 hour). Thus, the TLA-embedded PC particles were loaded with NO.

[0422] Tape preparation NO-loaded PC particles (100 mg) were placed in a scintillation vial (20 mL). To the vial, aqueous polyurethane dispersion (1.2 mL, Baymedix CD104, COVESTRO, Pittsburg, PA) was added and suspended in the dispersion using a laboratory vortex mixer (10 seconds). The mixture was coated onto a siliconized release liner using a doctor blade film coater. The film was dried in a vacuum chamber (-30 inHg for 1 hour) to obtain a polyurethane film (0.30 mm thick) with NO-loaded PC particles embedded therein.

[0423] The contents of all documents mentioned herein are incorporated by reference for all purposes.

[0424] Those skilled in the art will recognize medical devices (existing or developed in the future) that may not yet be known to them, as well as devices that can deliver light to tissues surrounding an injected biosensor, for example, in conjunction with biosensors other than those that operate via a glucose oxidase mechanism, all of which are within the scope of devices that can be used to practice the methods described herein.

Claims

1. A medical device, comprising: a) one or more polymers, wherein i) the polymer contains an NO-releasing functional group, or ii) the polymer is blended with particles or small molecules containing the NO-releasing functional group, and the medical device comprises a polymer coating containing the polymer.

2. The medical device according to claim 1, wherein at least one of the polymers is biocompatible and / or biodegradable.

3. The medical device according to claim 1, wherein at least one of the polymers is biocompatible and non-biodegradable.

4. The medical device according to claim 1, wherein the polymer is hydrophobic.

5. The medical device according to claim 1, wherein the polymer is formed from a mixture containing lactic acid, glycolic acid, carbonate, amino acid or caprolactone monomer, or a mixture thereof, and also contains one or more thiol-containing monomers, and all or part of the thiol groups on the thiol-containing monomers are converted to nitrosothiol.

6. The medical device according to claim 1, wherein the device is a transdermal implant or a subcutaneous implant.

7. The transdermal implant is an implantable glucose sensor, and the implantable glucose sensor comprises i) a first part which is an effective detection area, and ii) a second part which operably connects the effective detection area to the rest of the transdermal glucose monitor and enables the effective detection area to penetrate the user's skin to a desired depth for measuring glucose levels, and a transdermal glucose monitor comprising the implantable glucose sensor and an NO-releasing polymer coating on all or part of the second part of the implantable glucose sensor.

8. The polymer coating comprises a porous polymer disposed on all or part of the first part and the second part of the glucose sensor, a) the porous polymer used to form the coating contains one or more NO-releasing functional groups, b) the porous polymer used to form the coating contains one or more embedded particles, and the particles contain a polymer containing one or more NO-releasing functional groups. c) the porous polymer used to form the coating has a molecular weight of less than 1,000 and is blended with one or more small molecules containing one or more NO-releasing functional groups, or d) combinations thereof, the transdermal glucose monitor according to claim 7. **Claim 9** The medical device according to claim 4, wherein the hydrophobic polymer is a hydrophobic polyurethane. **Claim 10** The medical device according to claim 7, wherein the particles are formed from a polymer containing lactic acid, glycolic acid, and thiolactic acid monomers, and one or more thiol functional groups on the thiolactic acid monomers are converted to nitrosothiol groups. **Claim 11** The medical device according to claim 6, wherein the device is an artificial joint, a stent, a shunt, a port, an insulin infusion set, a catheter, a pacemaker, or a reconstructive aesthetic implant. **Claim 12** The medical device according to claim 6, wherein the polymer coating contains a hydrophobic polymer. **Claim 13** The medical device according to claim 12, wherein the hydrophobic polymer is a hydrophobic polyurethane. **Claim 14** The medical device according to claim 12, wherein the particles are formed from a polymer containing lactic acid, glycolic acid, and thiolactic acid monomers, and one or more thiol functional groups on the thiolactic acid monomers are converted to nitrosothiol groups. **Claim 15** A medical device comprising a polymer containing one or more NO-releasing functional groups and / or embedded particles and / or small molecules containing the NO-releasing functional groups. **Claim 16** The medical device according to claim 15, wherein the device is an absorbent or non-absorbent stitch, staple, monolith, or tape incorporating a NO-releasing group. **Claim 17** The medical device according to claim 16, wherein the monolith or the tape is physically or chemically attached to the medical device. **Claim 18** The medical device according to claim 15, wherein the device is an absorbent or non-absorbent tissue scaffold. **Claim 19** The medical device according to claim 15, wherein the polymer is a hydrophobic polymer. **Claim 20** The medical device according to claim 15, wherein the particles are formed from a polymer containing lactic acid, glycolic acid, and thiolactic acid monomers, and one or more thiol functional groups on the thiolactic acid monomers are converted to nitrosothiol groups. **Claim 21** A method for delivering nitric oxide from the surface of a biomedical implant, the method comprising implanting the implant according to claim 1 into a patient and, after implantation, exposing the NO-releasing groups on the polymer surface to a biological fluid, thereby causing the groups to release nitric oxide.

22. A method for measuring blood glucose concentration, comprising a) implanting the implantable glucose sensor of the transcutaneous glucose monitor according to claim 7 into a patient; b) measuring the blood glucose concentration using the transcutaneous glucose monitor and, simultaneously exposing the NO-releasing groups on the polymer coating to a biological fluid, causing the groups to release nitric oxide, wherein nitric oxide release occurs over a period of at least 3 days.

23. A medical device comprising a film formed by the application of an adhered tape or monolith, or a sprayable polymer formulation, wherein the tape, the monolith or the film comprises i) contains NO-releasing functional groups, or ii) is blended with particles or small molecules containing the NO-releasing functional groups, and comprises one or more biodegradable polymers, wherein the medical device is a sensory implant, a nerve implant, a cardiac implant, an orthopedic implant, an electrical implant, a contraceptive implant or a cosmetic implant.

24. The medical device according to claim 23, wherein the polymer in the tape, the monolith or the applied film is formed from a mixture comprising lactic acid, glycolic acid, carbonate, amino acid or caprolactone monomers, or mixtures thereof, and also comprises one or more thiol-containing monomers, and all or a portion of the thiol groups on the thiol-containing monomers are converted to nitrosothiols.

25. The medical device according to claim 23, wherein the device is a transdermal implant or a subcutaneous implant.

26. The medical device according to claim 23, wherein the device is an artificial joint, a stent, a shunt, a port, an insulin infusion set, a catheter, a pacemaker or a reconstructive cosmetic implant.

27. The medical device according to claim 23, wherein the monolith or the tape is physically or chemically attached to the medical device.

28. The medical device according to claim 23, wherein all or a part of the device is porous.

29. The medical device according to claim 28, wherein the sprayable formulation is applied to and at least partially fills one or more of the pores.

30. A method for delivering nitric oxide from the surface of a biomedical implant, comprising implanting the implant according to claim 23 into a patient and, after implantation, exposing the NO-releasing groups on the polymer surface to a biological fluid, thereby releasing nitric oxide from the groups.

31. A method for modifying a medical device to release nitric oxide, comprising: a) adhering a tape or a monolith to the medical device, wherein the tape or the monolith contains one or more pendant NO-releasing functional groups and / or a polymer incorporating embedded particles or small molecules containing one or more pendant NO-releasing functional groups, or b) a sprayable composition, comprising: i) a polymer containing one or more pendant NO-releasing functional groups, and ii) a sprayable composition containing a polymer containing one or more pendant NO-releasing functional groups, as well as particles and / or small molecules, spraying the medical device before implantation of the device in the patient or before application of the device thereon as a patient, and c) implanting the device in the patient or applying the device on the patient.

Images